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Targeting Histone deacetylases (HDAC) for the
treatment of genetically complex soft tissue sarcoma
Publication No. ___________
Gonzalo Lopez, MS
Supervisory Professor: Dina Lev, MD

Histone deactylase inhibitors (HDACi) are a new class of anticancer therapeutics;
however, little is known about HDACi or the individual contribution of HDAC isoform
activity in soft tissue sarcoma (STS). We investigated the potential efficacy of HDACi
as monotherapy and in combination with chemotherapy in a panel of genetically
complex STS. We found that HDACi combined with chemotherapy significantly
induced anti-STS effects in vitro and in vivo. We then focused our study of HDACi in
malignant peripheral nerve sheath tumor (MPNST), a subtype of highly aggressive,
therapeutically resistant, and commonly fatal malignancies that occur in patients with
neurofibromatosis type-1 (NF1) or sporadically. The therapeutic efficacy of HDACi was
investigated in a panel of NF1-associated and sporadic MPNST cell lines. Our results
demonstrate the NF1-assocaited cohort to be highly sensitive to HDACi while sporadic
cell lines exhibited resistance. HDACi-induced productive autophagy was found to be
a mode of resistance and inhibiting HDACi-induced autophagy significantly induced
pro-apoptotic effects of HDACi in vitro and in vivo. HDACs are not a single enzyme
consisting of 11 currently known isoforms. HDACis used in these studies inhibit a
variety of these isoforms, namely class I HDACs which include HDAC1, 2, 3, and 8.
Recently, HDAC8-specific inhibitors (HDAC8i) have been created and tested in
v

various cancer cell lines. Lastly, the potential therapeutic efficacy of HDAC8i was
investigated in human (NF1-associated and sporadic) and NF1-associated murinederived MPNST. HDAC8i abrogated cell growth in human and murine-derived MPNST
cells. Similar to the pattern noticed with pan-HDACis NF1-associated cells, especially
murine-derived, were more sensitive to HDAC8i compared to human sporadic MPNST
cell lines. S-phase arrest was observed in human and murine MPNST cells,
independent of p53 mutational and NF1 status. HDAC8i induced apoptosis is all cell
lines tested, with a more pronounced effects in human and murine-derived NF1associated cells. Most importantly, HDAC8i abrogated murine-derived MPNST
xenograft growth in vivo. Taken together, these findings support the evaluation of panHDACi and isoform-specific inhibitors as a novel therapy to treat MPNST, including in
combination with autophagy blocking combination regimens in particular for patients
with sporadic MPNST.
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Chapter I: Introduction
Section 1: Genetically complex soft tissue sarcoma (STS)
1.1 Epidemiology and etiology
“Cancer” as a disease has been described and treated with methods of the time
that date back to ancient Egypt around 1500 B.C. In the campaign against cancer it is
important to identify that malignant disease is not a single entity. Sarcoma and
carcinoma make up most solid tumors; however, sarcoma is not equal to carcinoma.
Sarcomas are heterogeneous tumors that are different from other cancers based on
their germ layer origin, sarcoma arises
from mesenchymal tissues and carcinoma
arise epithelial tissues (1). Sarcoma is
divided into sarcoma of the bone and soft
tissue sarcoma (STS) which entail
numerous subclasses based on the tissue
of origin. STS have a ubiquitous
distribution throughout the body with a
higher propensity to develop in the lower
extremities (Fig. 1). STS constitute 1% of
all adult cancers and occur at a higher
frequency in children at about 15% of all
neoplasms. The incidence of this disease
is about 10 – 12,000 new cases per year in
1

Figure 1. Anatomic distribution of
sarcomas. Sarcomas can arise
anywhere in the human body. This data
is from UTMDACC Sarcoma Surgical
Database (1996–2005). Modified from
Figure 3, Lahat et al. Surg Clin N Am
2008 88,451–481.

the US; where about 4,000 of these patients succumb to the disease (1). According to
the Surveillance Epidemiology and End Results (SEER) database the incidence ratio
of STS men are more likely to develop the disease compared to women (2). Relative
to other cancers; not much is known about the epidemiology of STS (2). Sarcomas in
general are a main cause of neoplastic-related deaths throughout the first two decades
of life and account for the 5th leading cause of in men under 20 years old and the 4th
leading cause of malignancy-related deaths in women under 20 years of age (3).
STS are believed to arise spontaneously with little known about causes of the disease.
In rare occasions inherited conditions are known to predispose some individuals to
developing STS. One such condition, Li-Fraumeni syndrome comprises a TP53 gene
(encodes the protein p53) mutation potentially leading to the predisposing of malignant
disease (4, 5). Retinoblastoma is a malignancy initiated by a mutation in the RB1
gene. Mutation of this tumor suppressor may occur spontaneously or hereditarily (6,
7). The loss of tumor suppressor NF1 is a common feature in patients with MPNST.
NF1 loss can occur under heritable or spontaneous conditions. While NF1 loss is a
major driving force for the development of MPNST, this malignancy can develop in
patients without NF1 (8, 9). As it is known to be a risk for the development of many
cancers, ionizing radiation increases the risk for the future development of MPNST. It
is well documented that women previously treated with radiation for breast cancer,
have a high chance of developing angiosarcoma (10). In light of these potential risk
factors, individuals diagnosed with STS have >15% risk of developing a second cancer
in the future.
2

1.2 Biological features of STS; patterns of disease
The biological behavior of STS is exceedingly variable. The histological grade of the
tumor is a major prognosticator on the behavior of the disease. Mitotic count,
cellularity, necrosis, differentiation, and stromal content are factors used to determine
histological grade (11). Low grade STS have low mitotic rates with a low risk of
metastatic disease, however, these low grade tumors have a high risk for local
recurrence (12). High grade STS have a high mitotic rate, exhibit invasiveness to local
tissue and have a high risk of metastatic spread. For patients with high grade STS,
metastatic disease most commonly occurs in the lungs. While lung metastases
commonly arise from primary tumors of the extremities, they can occur from nearly any
primary site or histology (12, 13).

1.3 Histological classification
As previously alluded to, STS
is not a single entity and
comprises about 50
histological subtypes (14)
(Fig. 2). Sarcomas are
molecularly grouped into two
cohorts: sarcomas with
specific reciprocal
translocations and relatively

Figure 2. Cross-section of leg showing sarcoma
differentiation. Sarcomas show recognizable
differentiation from normal mesenchymal tissues.
Some sarcomas lack recognizable differentiation
from any mesenchymal tissue, such as Ewing’s
sarcoma and synovial sarcoma. Modified from Figure
1, Lahat et al. Surg Clin N Am 2008 88,451–481.
3

simple karyotypes, and sarcomas with complex, unbalanced karyotypes, with no
specific translocations. Simple karyotypic sarcomas make up about 1/3 of all sarcomas
with 15 of these sarcomas of various histologies. These simple karyotypic sarcomas
possess over 25 different translocations with a majority of the derived fusion genes
creating aberrant chimeric transcription factors with the latter producing aberrant
kinases (2). These translocations biologically translate into transcriptional deregulation
or aberrant signaling which entail an important determinant toward a specific therapy.
Complex karyotypic sarcomas make up about 2/3 of all sarcomas in adults with a
dynamic biology consisting of aberrations such as genetic gains and losses,
chromosomal instability, and telomere dysfunctions. Diagnostically, the fusion genes of
simple karyotypic sarcomas make for excellent molecular markers whereas complex
karyotypic sarcomas; due to their multiple aberrations do not have bona fide diagnostic
molecular markers.
1.4 Diagnosis and Treatment
STS is typically diagnosed in individuals at a median age of 56 years of age. A small
percentage (about 10%) of patients less than 20 years of age are diagnosed with STS
where patients over 55 years of age make up about 50% of STS diagnoses (2). The
signs and symptoms of STS are not specific where most patients present with a
painless and palpable mass. In a third of the presented cases, STS-induced pain is
observed (15). Sarcomas growing in the abdominal and pelvic cavities may progress
undetected over long periods of time barring symptoms resulting in a delayed
diagnosis. Timely diagnosis and referral are advantageous, as the size of the tumor at
4

presentation is an incessant variable for the possibility of recurrence and metastasis
(15).
To date, STS are typically treated using a multidisciplinary approach which includes
surgery, chemotherapy, and radiation. As we continue to grasp a better
comprehension on the diverse natural history, biology, and therapeutic response of
STS; personalized therapy based on histology will be commonplace. Currently,
surgical resection occasionally supplemented with radiotherapy, of the tumor remains
the mainstay of therapy. While surgery and radiotherapy are used to treat localized
tumors, chemotherapy is used to control manifestations of systemic disease. For
metastatic disease, chemo- and/or radiotherapy are used to help with problems
associated with metastasis, whereas surgery at this unfortunate stage is used for
palliation.
1.5 Outcome
The prognosis for patients with STS is predicted using nomograms established on
tumor grade, tumor size, depth of the tumor, diagnosis, and age of the patient (16).
Local recurrence is associated with tumor grade, margins (from surgical resection),
and/or the use of radiation (14). Low grade STS have a chance of relapse beyond the
5 year diagnosis; where High grade STS usually occur within the first 5 years upon
diagnosis (14).

5

More than 50% of STS patients that develop distant metastasis regrettably succumb to
the disease. Patients diagnosed with metastases have a median survival of about 12
months from diagnosis (17, 18).
One of the more dismally aggressive complex karyotypic STS is malignant peripheral
nerve sheath tumors (MPNST).

6

Section 2: Malignant peripheral nerve sheath tumors (MPNSTs); an aggressive subset
of genetically complex STS
2.1 Epidemiology
MPNST make up about 3-10% of STS (19-21). More than 50% of patients that present
with MPNST develop the disease within the background of an inherited disease known
neurofibromatosis type I (NF1); the latter portion of MPNST patients develop the
disease sporadically (22). The molecular hallmark of neurofibromatosis is the loss of
the tumor suppressor neurofibromin,
known for its role as a regulator of Ras
(23-25). The incidence rate of
developing MPNST among NF1
patients occurs at 8 – 12% (22). Among
NF1 patients, loss of heterozygocity of

the NF1 gene occurs resulting in the
development of benign superficial
neurofibromas. Thirty to forty percent of
the neurofibromas that develop grow
deep (plexiform) within the NF1 patient
and have an 8 – 13% lifetime risk of
undergoing malignant transformation to

Figure 3. Natural history of MPNST
development. In the natural history of this
disease, a child is born with heterozygous
loss of NF1. As they grow, there is a loss
of heterozygocity in Schwann cells leading
to formation of neurofibromas, which in
most cases are superficial or dermal.
About 30-40% will develop deep plexiform
neurofibromas. 8-13% of these plexiform
neurofibromas acquire the loss of other
genes, such as p53 and undergo malignant
transformation to become an MPNST.

become MPNST (25) (Fig. 3).
7

Neurofibromin loss alone does not translate to the malignant transformation, as other
molecular derangements must occur to induce malignant transformation (25).

2.2 Diagnosis and Treatment
Upon diagnosis of MPNST, patients undergo a physical examination with a thorough
observation of their patient history. Prior to acquiring a biopsy of the potential tumor, a
radiological image of the patient is obtained. A common imaging modality for MPNST
is with the use of magnetic resonance imaging (MRI), which may differentiate
neurogenic tumors from non-neurogenic tumors of the soft tissues. Despite the
imperative diagnostic role of MRI, this method lacks the ability to distinguish benign
from malignant tumors, thus
mandating the use of microscopic
analysis of the tissue (Fig. 4). The
criteria required to confirm the
diagnosis of MPNST is based on
one of the following settings: the
tumor developed in association
with a peripheral nerve or a
plexiform neurofibroma, with
features that are histologically
compatible with MPNST. The

Figure 4. Diagnosis of MPNST . PET scan and
gross cross-section of MPNST. (courtesy of Dr.
Keila E. Torres, MD Anderson Cancer Center,
Houston, TX)

8

tumor histologically resembles an MPNST which has developed in a NF1 patient, the
tumor exhibits the definite histological characteristics of an MPNST (26, 27).
Complete surgical resection remains the primary mode of localized therapy. The aim
of this front line treatment modality is complete surgical resection of the tumor with
negative wide margins. Similar to its overall role in STS, systemic control of the
disease by chemotherapy endures as a controversial therapy for MPNST (28-30).

2.3 Outcome
Diagnosis of MPNST unfortunately translates into a dismal prognosis, where many of
these patients have non-resectable disease upon presentation. Patients who are
diagnosed with primary disease have a 10-year disease-specific survival at about
30%; however, this 10-year disease-specific survival drops to 26% in those with
recurrent MPNST (28, 31). Patients with advanced disease (non-resectable and/or
metastatic) respond poorly to chemotherapeutic intervention. The 5-year survival rate
for patients with advanced disease is unfavorably at 20-50% (25), and the 10-year
disease-specific survival is less than 8% (28).
Complex karyotypic sarcomas including MPNST have an array of molecular
derangements, where targeting a single molecule among the vast derangements
would not be a rational form of therapy. A therapeutic strategy to combat the
heterogeneous nature of complex karyotypic STS would be ideal. Histone deacetylase

9

(HDAC) inhibition is one such strategy that has been shown to induce a multitude of
anti-cancer effects.

Section 3: HDACs and the role of broad spectrum and isoform-specific HDAC
inhibitors in cancer
HDACs are a family of enzymes that deacetylate lysines on the core histones inducing
the condensation of chromatin. Histone acetyltransferases (HAT) are the counterpart
to HDACs as they acetylate lysine residues inducing an uncoiled conformation of
chromatin. The balance of HDAC and HAT activity plays a significant role in
epigenetics. This acetylation/deacetylation of lysine tails on histones was the initial
consensus of HDACs and HATs (hence their name), however, various non-histone
proteins, such as p53, β-catenin, Rb, NFκB, and E2F family members among various
other protein substrates, were also discovered to be acetylated/deacetylated.
Currently, eleven HDAC isoforms have been identified, including seven sirtuin
isoforms (Nicotinamide adenine dinucleotide (NAD)+-dependent enzymes with
deacetylase activity) in mammals (32, 33). HDACs have a catalytic domain that
requires a metal ion (i.e. Zn, Fe) coordinates with oxygen of its carbonyl group to
activate a water molecule with the support of histidine-aspartic acid for a nucleophilic
attack resulting in the acetyl group to be removed from the target protein lysine
residue. These isoforms (herein, only discussing HDAC isoforms), are organized into
four classes based on sequence identity and domain organization (34, Fig. 5). Class I
HDACs were initially believed to remain exclusively in the nucleus. However, HDAC3
10

Figure 5. Schematic depiction of HDAC isoforms and their sub-cellular localization. Bars
depict the length of each isoform. Amino acid (aa) length is depicted on the right of each
bar. Grey depicts the metal ion-dependent catalytic domain.
Black depicts the nuclear localization sequence (NLS). N = N-terminus, C = C-terminus.
Left column represents the sub-cellular localization of each isoform.

and HDAC8 have been shown to be expressed in the nucleus and cytoplasm. Similar
to HDAC3 and HDAC8, Class IIa and Class IIb HDACs have been shown to occur in
both the nuclear and cytoplasmic compartments of various cells. HDAC6 and HDAC10
have both been shown to play a cytoplasmic role more so than a nuclear role. Class IV
solely consists of HDAC11 which share similarities to Class I and II HDACs.
Mechanistically, HDACis work by chelating to the metal ion in the active site of
individual HDAC isoforms inhibiting its deacetylation ability (35).
The first experiments with compounds shown to inhibit HDACs were conducted in
murine erythroleukemia cells (MELC) by various groups. Differentiation of the MELC
cells occurred when treated with DMSO (36), TSA (37) or hexamethylene
11

bisacetamide (HMBA) (38). Trichostatin a (TSA) is a natural, hydroxamate-based
compound, which was first discovered to induce hyperacetylation of histones by
inhibiting HDAC isoforms (37). From these observations, compounds that share
structural similarity to DMSO were created (38, 39).
Suberoylanilide hydroxamic acid (SAHA), similar in structure to TSA, is one of the
early, synthetically available HDACis shown to hyperacetylate histones, induce
differentiation and inhibit proliferation in cancer cells at nanomolar ranges (38). Since
these initial evaluations, several other natural HDACi compounds have been
discovered along with the development of various synthetic HDACis of different
chemical backgrounds. Due to its efficacy in transformed cells, SAHA
(Vorinostat/Zolinza) was the first HDACi approved by the FDA (Food and Drug
Administration) for the clinical use against cutaneous T cell lymphoma (CTCL) (40,
41).
Since these promising effects, the monotherapeutic efficacies of HDACis are being
evaluated in preclinical in vitro and in vivo models in a variety of malignancies of
different histologies. Many preclinical studies have lead way to the use of a variety of
HDACis in clinical trials to evaluate the efficacy and toxicity of the drugs. Clinically,
HDACis alone or in combination with another anti-cancer therapy (chemotherapy,
radiotherapy) have generated promising anti-tumor activity. Currently, there are
around 50 clinical trials evaluating the monotherapeutic efficacy of a variety of HDACis
in cancers of various histology and more than 100 clinical trials evaluating the efficacy
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of HDACis combined with various chemotherapeutic compounds
(http://www.clinicaltrials.gov/, http://www.cancer.gov/clinicaltrials).
The study of the efficacy of HDACis in sarcoma is limited. One of the earliest studies
of HDACis in sarcoma occurred in 2002 where MS-275 was shown to have marked
anti-cancer activity in pediatric osteosarcoma, malignant rhabdoid tumors, Ewing's
sarcoma, and undifferentiated sarcoma (42). HDACis have also been shown to have
superior efficacy in simple karyotypic soft tissue sarcomas including, synovial sarcoma
(43-46), GIST (47), rhabdomyosarcoma (48-51) and complex karyotypic sarcomas
such as fibrosarcoma (50, 52-54), leiomyosarcoma (50, 55), and MPNST (56, 57).
Most of the HDACis currently used are broad-spectrum/pan inhibitors and target many
HDAC isoforms with a high affinity to Class I HDACs, namely HDAC1, 2, 3. Due to the
broad spectrum inhibition of these compounds, not much is known regarding the
individual contribution of each HDAC isoform toward various malignancies. Inhibiting a
multitude of HDACs has side effects where isoforms important for the tumorigenic
nature are inhibited while redundant HDAC isoforms are also blocked resulting in
undesirable effects on normal physiology. Park et al. (58) showed that by specifically
inhibiting (via siRNA KD) HDAC1, 6, and 8 but not HDAC4 decreased matrix
metalloproteinase 9 (MMP9) expression and the invasive capacity of breast cancer
cells. This observation further illustrates the importance of individual HDACs and their
contribution toward certain malignancies; owing toward the development of inhibitors
for individual HDAC isoforms.
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Recently, the development of HDAC8-specific inhibitors has paved a way to
understanding the contribution of certain isoforms individually. Currently, specific
inhibitors for HDAC6 (e.g. tubacin, tubastatin a) and HDAC8 are the only two isoform
specific compounds, where the development of specific inhibitors for isoforms are
underway. HDAC8’s structural uniqueness (59) from other class I HDAC isoforms has
resulted in its isolation and subsequent crystallography structure, allowing for the
development of specific inhibitors.
The HDAC8 gene, located on the Xq13 chromosome, encodes a 377 amino acid long
protein. Where classical class I HDACs are phosphorylated by casein kinase proteins,
HDAC8 is phosphorylated at serine 39 by cyclic AMP-dependent protein kinase A
(PKA) (60). Similar to other class I HDAC isoforms, HDAC8 possesses a nuclear
localization sequence (NLS) in its catalytic domain. Unlike the ubiquitous distribution
and expression of the other class I HDACs, HDAC8 has varying distribution among
human tissues. HDAC8 has been shown to be at a higher expression in the brain and
pancreas compared to HDAC1 and HDAC3, but at a lower expression level in other
organs (i.e. heart, placenta, kidney, liver) compared to other class I HDACs (61, 62).
Similar to other class I HDACs, HDAC8 expression is elevated in cancers of various
histologies (61, 62).
To date, little is known about the role of HDAC8 in normal physiology and cancer. Its
role in the hyperacetylation of histones remains controversial where HDAC8 has been
shown to deacetylate histones 3 and histone 4 in certain cells types, but not in others
(63, 64). Among the few deacetylation targets, HDAC8-mediated deacetylation of
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estrogen-related receptor alpha (ERRα) enhanced its DNA binding affinity, thus
enacting its role in transcriptional regulation of various processes (65). Nondeacetylation roles of HDAC8 have been identified. Phosphorylated-HDAC8 was
shown to interact with human ever shorter telomeres 1B (hEST1B) by recruit Hsp70 to
a complex that inhibits C-terminal heat shock protein interacting protein (CHIP), an E3
ubiquitin ligase. This pHDAC8-mediated protection of hEST1B was independent of its
acetylation state. Recent studies have shown that cytoplasmic HDAC8 interacts with
smooth muscle alpha-actin (α-SMA) in muscle cells undergoing differentiation (66).
Cytoplasmic HDAC8 has also been shown to have a diagnostic role in uterine
mesenchymal tumors (67).
Recently, three compounds with high affinities toward HDAC8 have been developed
and are in current cancer-related studies: compound 2/HDAC inhibitor XIX
(commercially available), PCI-34051, PCI-48012.
HDAC8-specific inhibitor PCI-34051 (PCI3) is a potent inhibitor with a 4,200-fold
selectivity over other HDAC isoforms. This compound was shown to induce apoptosis
in T-cell lymphoma and leukemia cells lines, but not in cells derived from other B-cell
or solid tumor cells lines (i.e. lung, colon, cervix, glioma, colon, breast ovarian).
However, distinct from pan-HDACis, PCI3 did not induce the hyperacetylation of
histones or tubulin in the cell lines tested (68).
In neuroblastoma, HDAC8 expression was shown to correlate with an unfavorable
outcome (69). Compound 2, a linkerless hydroxamate HDAC inhibitor with high
specificity to HDAC8 was recently created (70), and tested on neuroblastoma cell
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lines. Knockdown of HDAC8 as well as with the use of compound 2 induced the
differentiation of neuroblastoma cell lines by stimulating the outgrowth neuritic-like
structures. Inhibition of HDAC8 either by knockdown or by compound 2 abrogated
neuroblastoma cell line proliferation, but did not induce apoptosis. HDAC8 inhibitioninduced expression of p21Waf1/Cip1 and NTRK1/TrkA was associated with the
neuroblastoma cell line growth inhibition (69, 71). Interestingly, both neuroblastoma
and MPNST derive from neural crest cell origins, suggesting a potential role for
HDAC8 in the progression of these malignancies.

16

Chapter II: Hypothesis

HDAC inhibition is a potentially novel therapy for the treatment of genetically complex
STS.
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Chapter III: Aims

Aim 1: To preclinically determine the potential relevance of HDAC inhibition as a
therapeutic modality for the treatment of genetically complex STS.
1.1: Determine the effect pan-HDACi as a single agent
1.2: Evaluate the role of pan-HDACi in combination with chemotherapy

Aim 2: To test the efficacy of pan-HDACi for the treatment of MPNST
2.1 Determine the efficacy of pan-HDACi in vitro and in vivo
2.2 Identify the mechanisms of sensitivity and resistance to HDACi

Aim 3: To assess the impact of HDAC8 inhibition on MPNST growth and protumorigenic phenotype
3.1 Determine the effect of HDAC8 inhibition in vitro
3.2 Ascertain the effect of HDAC8 inhibition in vivo
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Chapter IV: Significance

There is a critical need for novel therapeutic strategies to improve the dismal outcome
of patients suffering from high grade STS and aggressive subtypes such as MPNST.
In this pre-clinical study we show the promising efficacy of pan- and isoform-specific
HDAC inhibition in a panel of genetically complex STS, namely MPNST. This report
also gives insight into the molecular contributors influencing therapeutic resistance that
can be circumvented by rational combination therapies. Initial findings from this study
have been factorial in the launch of clinical trials evaluating the effect of pan-HDAC
inhibition combined with chemotherapy for patients with high grade sarcomas. This
report emphasizes the importance of these preclinical models for the utility of HDAC
inhibition in sarcoma, a malignancy with limited therapeutic avenues.
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Chapter V: Materials and Methods:

Cell lines
Human HT1080 (fibrosarcoma), RD (rhabdomyosarcoma), and SKLMS1
(leiomyosarcoma) STS cells were obtained from the American Type Culture
Collection. Primary normal human fibroblast (NHF) cultures were acquired from
Promocell GmbH. MPNST cell lines utilized in these studies included the NF1associated: ST88 (provided by Dr Jonathan Fletcher, Brigham and Women’s Hospital,
Boston, MA), T265 (provided by Dr George De Vries, Hines VA Hospital, Hines, IL),
S462 (provided by Dr Brian Rubin, Cleveland Clinic, Cleveland, OH) and the
MPNST642 isolated in our laboratory and the sporadic MPNST cell lines: STS26T
(provided by Dr Steven Porcelli, Albert Einstein College of Medicine, Bronx, NY) and
MPNST724 (provided by Dr Jonathan Fletcher) and were propagated and maintained
as previously described (72). Murine-derived MPNST cell lines, NF1-TG-05 and -09
were established in our laboratory and MPNST6IEP and MPNST6IEP4 were provided
by Dr. Luis Parada (The University of Texas Southwestern Medical Center, Dallas TX).
Primary human adult Schwann cell (NSC) cultures, used as controls for MPNST
experiments were established from human cauda equina nerves were provided by Dr
Patrick Wood (Miami Project, University of Miami, Miami, FL) and maintained as
previously described (73). ST88, STS26T and MPNST724 cells were stably
transfected to express GFP-LC3; overexpressing cells were FACS-sorted on the basis
of green fluorescent protein (GFP) expression. Cells were cultured in DMEM
20

supplemented with 10% FBS (Life Technologies). DNA fingerprinting (short tandem
repeat) was conducted for all cell lines less than 6 months prior to the conduct of the
studies, confirming that no cross-contamination has occurred.
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Antibodies

mAb Name

Company

Application

Ref

Rad51

Santa Cruz

WB

50

Ac.H3

Millipore

WB

50

Ac.H4

Millipore

WB

50

Ac.tubulin

Sigma

WB

50

β-actin

Santa Cruz

WB

50

CD31

BD Biosciences

IHC

50

PCNA

Dako Cytomation

IHC

50

E2F1

Santa Cruz

ChIP

50

E2F4

Santa Cruz

ChIP

50

RNA polymerase II

Covance

ChIP

50

IgG

Santa Cruz

ChIP

50

CTGF

Santa Cruz

WB

50

CHK1

Cell signaling

WB

50

Mouse IgG

Santa Cruz

ChIP

50

Rabbit IgG

Santa Cruz

ChIP

50

LC3B

Cell Signaling

WB

GFP

Santa Cruz

WB

Beclin 1

Santa Cruz

WB

56

p53

Santa Cruz

WB

56

Ki67

MIB-1

IHC

56

56
56
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IRGM

Abcam

WB

56

PARP

Abcam

WB

56

Caspase 3

Cell signaling

WB

56

NF1
Table 1. Antibodies

Santa Cruz

WB

56

Antibodies were used for WB, ChIP, and IHC. Secondary antibodies included
horseradish peroxidase–conjugated (Universal kit HRP; Biocare Medical) and
fluorescent secondary antibodies (anti-rabbit Alexa488 and anti-mouse Alexa 594;
Jackson Immuno Research). Other reagents included CytoQ FC Receptor block
(Innovex Bioscience), Hoechst 33342 (Polysciences), and propyl gallate (ACROS
Organics).
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Drugs/compounds
Compound
Class
Specificity
PCI-24781 (PCI2)
Hydroxamate
Broad spectrum
SAHA
Hydroxamate
Broad spectrum
MS-275
Benzamide
Class I
PCI-34051 (PCI3)
Hydroxamate
HDAC8
PCI-48012 (PCI4)
Hydroxamate
HDAC8
Table 2. HDAC inhibitors used in this study were reconstituted in DMSO for in vitro
studies. For in vivo use, PCI2 was dissolved in 50mM Sodium lactate, pH 4.2; PCI4
was dissolved in 0.5% methylcellulose.
Chemotherapeutic agents used in this study: Doxorubicin (Ben Venue Lab) and
cisplatinum (Sicor) were obtained from the MD Anderson Cancer Center Pharmacy.
Autophagy inhibitors: Bafilomycin A1 (Sigma; B1793) was reconstituted in DMSO and
was only used for in vitro studies; Chloroquine (Sigma; C6628) was reconstituted in
sterile deionized water and used for in vitro and in vivo studies.
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Kits
Kit
CellTiter96
Aqueous Non-Radioactive Cell Proliferation
Assay kit
Annevin V
cDNA 1st strand synthesis
Qiagen RNeasy® Mini Kit
TUNEL
ChIP

Company

Ref.

Promega
BD Biosciences
Roche
Qiagen
Promega
Upstate

50, 56
50, 56
50, 56
50
50, 56
50

Stratagene Quick Change mutagenesis kit
Stratagene
50
Ras activity assay
Cell Biolabs
56
Autophagy RT2 Profiler PCR Array
SA Biosciences
56
Table 3. Kits used in these studies were utilized per the manufacturer's instructions.
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Cell culture based assays
Western Blot
Western blot analysis was performed by standard methods. Briefly, 25 - 50μg of
proteins extracted from cultured cells were separated by SDS-PAGE and transferred
onto nitrocellulose membranes. Membranes were blocked and blotted with relevant
antibodies. HRP-conjugated secondary antibodies were detected by enhanced
chemiluminescence (Amersham Biosciences, Plc.).

Reverse transcriptase PCR (RTPCR) and Real time PCR (qRTPCR)
These experiments were conducted as we have previously described (74). Primers
used are depicted in the table below:
Gene
*Rad51
GAPDH
Rad51
p21
Actin
IRGM
CXCR4
TMEM74
NFkB1
ATG5
ATG7

Forward primer
TGGCCCACAACCCATTTCAC
GAGCCACATCGCTCAGAC
GAGGTGAAGGAAAGGCCATGT
GGAAGACCATGTGGACCTGT
CAGCCATGTACGTTGCTATCCAGG
CCCTTCGAAACACAGGACAT
GGTGGTCTATGTTGGCGTCT
TGACCAGGCAGATACAGCAG
CCTGGATGACTCTTGGGAAA
TGGGGTGGATATAGGGCATA
ACCCAGAAGAAGCTGAACGA

Reverse primer
TCAATGTACATGGCCTTTCCTTCAC
CTTCTCATGGTTCACACCC
GGGTCTGGTGGTCTGTGTTGA
AATCTGTCATGCTGGTCTGC
AGGTCCAGACGCAGGATGGCATG
AGTTCTCCAGGGTTGTGGTG
TGGAGTGTGACAGCTTGGAG
GTGGAGAAGTCCTGGTGGAA
TCAGCCAGCTGTTTCATGTC
GACCTGGAGCCAATGAAAAA
CTCATTTGCTGCTTGTTCCA

Table 4. Primer sequences used in these experiments. PCR primers for both assays
were designed using primer 3 software. Total RNA was isolated from cultured
STS/MPNST cells using TRIzol reagent (Invitrogen) per manufacturer's instructions.
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Total RNA (1μg) was reverse transcribed using SuperScript III reverse transcriptase
(Invitrogen) and 2μL of the product were used as templates. The PCR reaction mixture
contained 2× PCR Master Mix (Promega), 0.2μM of primers (each 0.5μM), and 2μL
cDNA. *Rad51 primers for RT-PCR. All other primers were designed for qRT-PCR.

Tumor growth assays
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay
Cell growth assays used CellTiter96 Aqueous Non-Radioactive Cell Proliferation
Assay kit (Promega) per the manufacturer's instructions. Growth rates were analyzed
48 - 96 h after HDACi (pan-HDACis: PCI-24781/SAHA/MS-275; HDAC8is: PCI-34051,
PCI-48012) treatment and with doxorubicin or cisplatinum alone or combined with
HDACi; several administration sequences were evaluated: 24 h pretreatment with
PCI2 followed by the addition of chemotherapy for 24 h and conversely, pretreatment
with chemotherapy followed by PCI2 as well as treatment with both compounds
concomitantly for 24 h. Absorbance was measured at 490 nm wavelength; treated cell
absorbance values are presented as a percentage of untreated cell absorbance.
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Clonogenic assay
STS and MPNST cells were plated at 100-200 cells per well in 6-well culture plates. 24
h after plating, the cells were treated with DMSO (control) and varying concentrations
of HDACi (pan-HDACis: PCI-24781/SAHA/MS-275; HDAC8is: PCI-34051, PCI-48012)
for 24 h or continuous treatment. In combination studies, MPNST cells were first
treated with an autophagy inhibitor (BFA/CQ) for 24 h then combined with HDACi for
an additional 24 h. After combination therapy the drugs were removed and fresh media
was added to the test wells; cells remained in fresh media (changed every 48 h) for 10
days. After 10 days, the cells were stained with a 6% glutaraldehyde, 0.5% crystal
violet solution for 30 min. Staining solution was decanted from each well and cells
washed with deionized H2O. Individual colonies retaining staining solution were
counted.

Cell cycle FACS analysis
Cells were treated with pan-HDACis (PCI-24781/SAHA) or HDAC8is (PCI-34051/PCI48012) for varying periods. Propidium iodide/fluorescence-activated cell sorting
(FACS) analysis was conducted as described (75).
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Apoptosis assays
Apoptosis was measured using the Apoptosis Detection kit I (BD Biosciences, San
Jose, CA) per manufacturer’s recommendations. As a standard, 1x106/mL of cells per
treatment condition (time and dose as indicated) were fixed and stained with 5μL
Annexin V–FITC (BD PharMingen, San Diego, CA) and 5μL propidium iodide (Sigma,
St Louis, MO). Flow cytometric analysis was performed for 1x104 cells and analyzed
by FACScan (Becton Dickinson, Franklin Lakes, NJ) using a single laser emitting
excitation light at 488 nm. Data were analyzed by CellQuest software (Becton Dickson,
Franklin Lakes, NJ). To confirm annexin V-FITC FACS results, WBs were conducted
on samples similarly used for annexin V-FITC FACS. Westerns were blotted for
apoptotic markers: cleaved caspase 3 and/or cleaved PARP.

Transfection procedures
siRNAs (pools targeting: beclin, ATG5, ATG7, IRGM, p53, and control non-targeting
constructs, Thermo Scientific, Dharmacon) were introduced into cells using XtremeGENE (Roche) per manufacturer’s instructions. Briefly, 2x105 cells were plated in
each well of a six-well plate and incubated overnight. A mixture of siRNA (20nM) and
X-tremeGENE diluted in Dulbecco's modified Eagle medium (DMEM) was added for
24 h, followed by incubation in regular medium. Cells were harvested at indicated time
points for specific experiments.
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p53 transfection
Adp53 and AdLacZ adenoviruses were produced and titered by the Vector Core
Laboratory at M.D. Anderson Cancer Center. Transfection procedures were conducted
as we have previously described (76).

Autophagy assays
Transmission electron microscopy (TEM)
MPNST cells were grown in 6-well culture plates and treated with PCI2 (1μM) or
DMSO alone for 24, 48, or 72 h and then fixed for one hour with a solution containing
3% glutaraldehyde plus 2% paraformaldehyde in 0.1M cacodylate buffer (pH 7.3).
After fixation, the samples were post-fixed in 1% OsO4 in the same buffer for 30min
then stained with 1% uranyl acetate. Representative areas were chosen for ultrathin
sectioning and electron microscopic viewing (JEM 1010 transmission electron
microscope; JEOL, Peabody, MA), as previously described (77). Digital images were
also obtained (AMT imaging system; Advanced Microscopy Techniques Corp.,
Danvers, MA). Three replicates were performed for each experiment.
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Acridine orange staining and FACS analysis
Autophagy was evaluated in MPNST cell lines by the staining of acidic vesicular
organelles as previously described (78, 79). Briefly, MPNST cell lines were treated
with pan-HDACis or DMSO (control). 48 h later, cells were stained with acridine
orange (1μg/mL; Sigma-Aldrich) for 15 min; samples were examined and images were
taken using a fluorescence microscope. For further quantification, cells were treated
and stained as above, trypsinized, and analyzed via flow cytometry. Green (510530nm) and red (>650nm) fluorescence emission from 2x104 cells illuminated with
blue (488nm) excitation light was measured using FACS Calibur (Becton Dickinson)
using CellQuest software.

LC3 conversion
Conversion of soluble LC3-I to lipid bound LC3-II is associated with the formation of
autophagosomes. Cleavage of LC3 at the carboxy terminus immediately following
synthesis yields the cytosolic LC3-I form. During autophagy, LC3-I is converted to
LC3-II through lipidation by a ubiquitin-like system involving Atg7 and Atg3 that allows
LC3 to become associated with autophagic vesicles. The presence of LC3 in
autophagosomes and the conversion of LC3 to the lower migrating form LC3-II have
been used as indicators of autophagy. WB for LC3 demonstrating enhanced
expression of LC3B-II (normalized to actin) is an indicator of increased number of
autophagosomes. The inhibitors chloroquine and bafilomycin block the last stages of
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productive autophagy thus will result in autophagosome accumulation; WB for LC3B-II
in the presence of these inhibitors is expected to show increased LC3B-II levels
(normalized to actin). Combining chloroquine or bafilomycin with compounds that
enhance productive autophagy is expected to show further increase in LC3B-II
expression.

GFP-LC3 puncta
MPNST cells were stably transfected to express GFP-LC3 (STS26T, MPNST724,
ST88); overexpressing cells were FACS-sorted on the basis of green fluorescent
protein (GFP). The presence and images of GFP-LC3 puncta was observed using
fluorescent microscopy.

GFP cleavage assay
When GFP-LC3 is delivered to a lysosome the LC3 part of the chimera is sensitive to
degradation, whereas the GFP protein is relatively resistant to hydrolysis. Therefore,
the appearance of free GFP on WB (blotted for GFP) can be used to monitor lysis of
the inner autophagosome membrane and breakdown of the cargo, indicative of
productive autophagy (79). Lysate preparation and western blotting of GFP-LC3 cells
samples were conducted as mentioned above.
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Therapeutic animal experiments

Effect of monotherapy on local xenograft growth
All animal procedures and care were approved by the MD Anderson Cancer Center
Institutional Animal Care and Usage Committee. Animals received humane care as
per the Animal Welfare Act and the NIH “Guide for the Care and Use of Laboratory
Animals.” Animal models were utilized as previously described (78). Trypan blue
staining confirmed viable cells (SKLMS1 or HT1080 cells 1x106/0.1 mL HBSS/mouse;
STS26T, MPNST724, or MPNST642 cells 1-2x106/0.1 mL HBSS/mouse;
MPNST6IEP4 cells 1x106/0.1 mL HBSS/mouse) were injected into the flank (SKLMS1
i.m., HT1080, STS26T, MPNST724, MPNST642, MPNST6IEPVI s.c.) of 6-wk-old
female SCID mice (MPNST cells were injected into hairless SCID mice), growth was
measured twice weekly. When average tumor volumes reached 100 mm3, the mice
were assigned to treatment groups (7-8 mice/group). STS/MPNST cells were allocated
into 2 treatment arms: Vehicle; HDACi/HDAC8i (PCI2 [25-50mg/kg BID 5X d/wk, i.p.];
PCI4 [20mg/kg BID 5X d/wk, i.p.]). PCI2/PCI4 dose and treatment schedules were
determined per company recommendations. The mice were followed for tumor size
and body weight and sacrificed when control group tumors reached 1.5 cm average
largest dimension. Tumors were resected, weighed, and frozen or fixed in formalin and
paraffin-embedded for immunohistochemical studies.
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Effect of monotherapy on autophagy
MPNST724 and STS26T GFP-LC3 cells were injected into the flank of hairless SCID
mice s.c. When palpable tumors reached average diameter ~10mm, STS26T GFPLC3 xenografts were treated with either vehicle or PCI2 (25mg/kg), and mice were
euthanized 2, 4, and 6 h after treatment. MPNST724 GFP-LC3 xenografts (when
average diameter ~10mm) were allocated into four treatment arms: Vehicle, PCI2
(25mg/kg), chloroquine (50mg/kg), PCI2 + CQ. Mice were treated with CQ a day prior
to combining with PCI2. Mice from these groups were euthanized after 24 h treatment
(groups receiving CQ were treated with this compound for 48 h). Resected tumors
were processed for lysate and analyzed on WB.

Effect of monotherapy on metastatic growth
HT1080GL (for studies in Lopez et al. 2009) or STS26TGL (for studies in Lopez et al.
2010) cells (stably expressing green fluorescent protein/Luciferase; GL) were tail vein
injected, resulting in experimental lung metastases that could be followed by
bioluminescence. A similar experimental design used for local growth experiments
were used for lung metastasis experiments. Treatment was initiated when
bioluminescence showed established lung metastases. The mice were followed and
euthanized when bioluminescence suggested control group had significant pulmonary
tumor load. Lungs were resected, weighed, and fixed in formalin for the creation of
paraffin blocks.
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Combined HDACis with conventional chemotherapy
For local growth studies, SKLMS1 or HT1080 cells (1x106/0.1 mL HBSS/mouse) were
injected s.c. into the flank of 6-wk-old female SCID mice; growth was measured twice
weekly. When average tumor volumes reached 100mm3, the mice were assigned to
treatment groups (7-8 mice/group). STS cells were allocated into 4 treatment arms: 1)
vehicle; 2) doxorubicin/cisplatinum (1.2mg/kg/biweekly and 2 mg/kg/biweekly,
respectively, i.p.); 3) PCI2 (50mg/kg BID 5X d/wk, i.p.); and 4) PCI2 + chemotherapy
(PCI2 initiated 24 h before chemotherapy in all cases). PCI2 dose and treatment
schedules were determined per company recommendations. The mice were followed
for tumor size and body weight and sacrificed when control group tumors reached 1.5
cm average largest dimension. Tumors were resected, weighed, and frozen or fixed in
formalin and paraffin-embedded for immunohistochemical studies.
For lung metastasis model, HT1080GL cells were used. Lung metastasis models were
conducted as mentioned above.
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Combined HDACi with autophagy blockade
For experiments evaluating effect of treatment on local tumor growth trypan blue
staining confirmed viable MPNST cells (MPNST642, MPNST724 and STS26T; 12x106/0.1 mL HBSS/mouse) were used. Cell suspensions were injected
subcutaneously into the flank of six week old female hairless SCID mice (n
=10/treatment group) and growth was measured twice weekly; after establishment of
palpable lesions (average diameter >5mm) mice were assigned to treatment groups as
described below. An experimental lung metastasis MPNST model was used to
evaluate metastases’ growth. STS26T cells (1x106/0.1 mL HBSS/mouse) were
injected into the tail vein of female SCID mice. Ten days after injection (a time-point by
which 95-100% of mice develop established lung metastases) mice were allocated to
treatment groups as per below. Therapeutic regimens included a four armed study: 1)
DMSO; 2) PCI2 (25mg/kg/d for five days/week); 3) chloroquine (50mg/kg/d for five
days a week); and, 4) combination of PCI2 and chloroquine. In the latter studies,
including a chloroquine arm, this drug was initiated a day prior to PCI2 treatment. Mice
were followed for tumor size, well-being, and body weight and sacrificed when control
group tumors reached an average of 1.5 cm in their largest dimension. Tumors were
resected, weighed, and frozen or fixed in formalin and paraffin-embedded for
immunohistochemical studies. For lung metastasis studies mice were followed for
body weight and well-being and sacrificed after two weeks of treatment. Lungs were
resected, evaluated macroscopically for tumor load and weighed.
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Tissue based experiments

Immunohistochemistry (IHC)
IHC and terminal deoxyribonucleotide transferase–mediated nick-end labeling
(TUNEL) assays were conducted on paraffin and frozen sections, respectively.
Conventional H&E staining was done (MD Anderson core facility) and examined by
light microscopy. IHC was done using anti-Ki67 (1:500; DAKO Carpinteria, CA), antiPCNA (1:500; DAKO Carpinteria, CA), and anti-CD31 (1:50; PharMingen, San Diego,
CA). Fluorometric TUNEL System (Promega; Madison, WI) was used to detect DNA
fragmentation on frozen sections as per the manufacturer’s protocol.

WB and RTPCR/qRTPCR (from in vivo tissues)
For protein lysates; cells were washed twice with cold PBS. Whole cell lysate was
added to the cells and the plate remained at 4°C for 20 min. The cells were then
scraped using a cell scraper and the lysate was placed in a 1.5mL pre-chilled
Eppendorf tube. The lysate was then placed on a rotator at 4°C for 20 min. The lysate
was then centrifuged at 140,000 rpm at 4°C for 10 min. The supernatant was
transferred to a fresh, 1.5mL pre-chilled Eppendorf tube and stored at -80°C until
further use.
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For mRNA-based experiments, cells were washed twice in cold PBS. TRIzol was
added to the cells and the plate was placed on a rocker for 10 min at room
temperature. After 10 min, samples were placed in a 1.5mL pre-chilled Eppendorf
tube.

High throughput experiments

Autophagy qRT-PCR array
Total RNA was isolated from MPNST724 and STS26T cells (PCI-24781 treated
[0.5μM/24h] and untreated) using TRIzol. After DNase treatment, RNA was further
cleaned up using Qiagen RNeasy® Mini Kit (Qiagen, Valencia, CA). cDNA was
synthesized by RT2 First Strand kit SABiosciences, Frederick, MD) following
manufacturer’s instructions. Gene expression profiling using the Autophagy RT2
ProfilerTM PCR Array (SABiosciences, Frederick, MD) was conducted. This platform is
designed to profile the expression of 84 key genes involved in autophagy (for a
comprehensive list of included genes see www.sabiosciences.com). qRTPCR was
conducted using Mastercycler Epgradients realplex (Eppendorf AG, Hamburg,
Germany) based on array manufacturer’s instructions. Relative gene expression was
determined using the ΔΔCT method. Data were further analyzed by PCR Array Data
Analysis Web Portal (www.SABiosciences.com/pcrarraydataanalysis.php). All
experiments were repeated twice.
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Statistics

Statistical analysis for tissue culture based experiments
Cell culture-based assays (and Western blot analyses) were repeated at least three
times; mean ± SD was calculated. Cell lines were examined separately. For outcomes
that were measured at a single time point a two-sample t-test was used to assess
differences; a linear mixed model was used to assess treatment effects and
association between compounds.

Statistical analysis for animal experiments
For STS and MPNST-based in vivo experiments (50, 56) the average (AVG),standard
deviation (STDV)/standard error mean (SEM), and range for all in vivo experiment
group variables were calculated and recorded. Tumor weights (g) and lung weights (g)
for each treatment group were measured for the following: 1st quartile, 3rd quartile,
maximum, minimum, median. All tumor weight and lung weight data are depicted as
box plots. The number of lung metastases for (56) are depicted as a dot plot. For
outcomes that were measured at a single time point, 2-sample t-tests were used to
assess the differences. Differences in xenograft growth (tumor/metastases) in vivo
were assessed using a 2-tailed Student's t-test. IHC analysis (Ki67, TUNEL) were
assessed using 2-tailed Student’s t-test. Significance was set at p ≤ 0.05.
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Chapter VI: Results

Section 1: Aim 1: The potential effects of HDACis on genetically complex STS
1.1 Effects as monotherapy
The goal of this initial set of studies was to evaluate the effects of pan-HDAC inhibitors
on the growth of genetically complex human STS cells in vitro. The hydroxamic acidbased pan-HDACis used were PCI2 and suberoylanilide hydroxamic acid
(SAHA/Vorinostat). To first confirm that these compounds truly inhibit HDAC activity in
our cell lines and induce protein acetylation in situ. The expression of acetylated
histone 3 and histone 4 and acetylated tubulin was via western blot. A time- and dosedependent increase in acetylated histones 3, 4 and tubulin was observed using both
compounds in human STS cell lines of diverse histology and differential p53 status:
Fibrosarcoma (HT1080, wild type p53), rhabdomyosarcoma (RD, mutated p53), and
leiomyosarcoma (SKLMS1, mutated p53) (Fig. 6).

Figure 6. Western blot analysis showing HDACi (PCI2 and SAHA) induced time- and
dose-dependent increase in histone 3, histone 4, and tubulin acetylation in STS cells.
This increase in acetylation is a marker for the HDAC inhibitory effect of these
compounds. Modified from Figure 1, Lopez et al. Clin Cancer Res 2009;15:3472-3483.
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We next evaluated the effects of HDAC inhibition on STS cell growth in vitro. Both
HDACis induced a dose-dependent decrease in cell growth after 48 h treatment, with
all three cell lines showing more sensitivity to PCI2 compared to SAHA when assayed
via MTS (Fig. 7A). No significant effect on the growth of normal human fibroblasts
(NHF) was observed. Resistance of normal cells to the effects of HDACi has been
previously reported (81), and our data repeated these findings. A marked effect on
STS clonogenic capacity was noted with both compounds (Fig. 7B). These
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Figure 7. A, MTS assays demonstrating the effect of HDAC inhibition (48 h) on STS cell
growth. Although STS cell growth inhibition was seen with both agents, a more
significant response to PCI2 was observed in cells tested. No effect was seen after
treatment of normal human fibroblasts (NHF). B, HDACis abrogate STS cell colony
formation capacity. Right panel, number of colonies counted in experiments repeated
three times. Results represent the average of a minimum of three replications (± SD).
Modified from Figure 1, Lopez et al. Clin Cancer Res 2009;15:3472-3483.

later assays were conducted using a 24 h treatment, the compounds were removed
and the cells were grown in normal media for 14 days.
Together these data suggest that HDACis inhibit the growth of genetically complex
STS cell lines regardless of histological subtype and differential p53 status, supporting
additional investigation on the impact of HDACis on STS in vitro and in vivo.
Next we aimed to determine whether HDACi-induced growth inhibition is secondary to
abrogated cell cycle progression and/or cell death. First, to assess the effect of
HDACis on the cell cycle, STS cell lines were treated with IC50 doses of both drugs for
48 h and propidium iodide (PI) staining/FACS were conducted. Both drugs were found
to induce G2/M cell cycle arrest, in the cell lines tested, independent of p53 mutational
status (Fig. 8A). For example, PCI2 (0.5μM) treatment for 48 h, resulted in decreased
proportion of S-phase cells from 42 ± 6.4% to 26 ± 9.1% and from 34 ± 5% to 17 ± 5%,
in RD (p53 mut.) and HT1080 (p53 wt) cells, respectively. Whereas G2/M phase cells
increased from 22 ± 1.7% to 64 ± 3.6% and from 30 ± 6.4% to 49 ± 5.7%, respectively
(p < 0.05). Similarly, SAHA induced S-phase depletion and G2/M arrest in both cell
lines. Cell cycle analyses also demonstrated an increase in the sub-G1 fraction in cell
lines treated with either HDACi, indicative of fragmented DNA, suggesting HDACiinduced cell death. To test whether increased sub-G1 fraction is the result of
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apoptosis, annexin V/PI staining FACS analyses were conducted. PCI2 induced
marked apoptosis in a dose- and time-dependent manner (Fig. 8B). Although only
minimal apoptosis was seen 24 h after exposure to PCI2, 74% ± 14 and 64% ± 25
Annexin V positivity was observed in HT1080 and RD cells, respectively, after 96 h of
PCI2 (0.5μM) treatment. In brief, HDAC inhibition abrogated STS growth by inducing
G2/M cell cycle arrest and apoptosis in vitro.
Prior to testing the effects of HDACis on STS growth in vitro we opted, as depicted in

Figure 8. A, PI staining/FACS analyses showing the effect of HDACis (PCI2 0.5 μM/48
h, SAHA 2 μM/48 h) on STS cell cycle progression. A significant (p < 0.05) reduction in S
phase cells and G2 arrest is seen. Additionally, an increase in sub G1 population is
observed, suggesting cell death. B, PCI2 induced STS cell apoptosis in a time- and
dose-dependent manner (Annexin V/PI staining FACS analyses). Modified from Figure 2,
Lopez et al. Clin Cancer Res 2009;15:3472-3483.
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the next section to identify HDACi-based therapeutic combinations that demonstrate
superior anti-STS effects as compared to monotherapy.

1.2 Combining HDACis with conventional chemotherapy
Multiple lines of evidence suggest that combining HDACis with conventional
chemotherapy and/or radiation, result in synergistic anti-cancer effects (82-84). We
aimed to determine if these
findings can be recapitulated
in STS. To that end we
examined the efficacy of low
dose PCI2 (0.1M) in
combination with low doses of

two different chemotherapeutic
drugs commonly used as a
treatment for STS: the
anthracycline drug doxorubicin
(0.5µM) and the DNA crosslinking drug, cisplatinum (1µM).
Cells were pretreated with PCI2

Figure 9. Pretreatment of STS cells with PCI2
(0.1μM/24h) sensitizes STS cells to chemotherapy.
A superior effect was shown when combining PCI2
and doxorubicin (0.5μM/24 h; p < 0.0001) or
cisplatinum (1μM/24h; p < 0.05) as compared with
each agent alone. When sequencing was reversed,
i.e. pretreatment with chemotherapy (24 h) followed
by the addition of PCI2 (24 h), or when the drugs
were administered concomitantly for 24 h, no such
superior effect was observed (data not shown).
Modified from Figure 2, Lopez et al. Clin Cancer Res
2009;15:3472-3483.

alone for 48 h, chemotherapy alone for 24 h, or by sequential combination of PCI2 and
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chemotherapy (cells pretreated with PCI2 for 24 h, then chemotherapy was added for
an additional 24 h). MTS assays were conducted at 48 h (Fig. 9). The combination of
PCI2 (0.1μM) and doxorubicin (0.5μM) caused growth reductions of 77% ± 4.7, 81% ±
3.1, and 65% ± 3.5 in HT1080, RD, and SKLMS1 cells, respectively. In contrast, low
dose PCI2 alone resulted in 23% ± 3.2, 24% ± 5.6, and 12% ± 4.4 growth inhibition of
HT1080, RD, and SKLMS1 cells, whereas low dose doxorubicin alone caused 6% ±
9.5, 10% ± 4.5, and 9% ± 4.5 growth reduction, respectively. Statistical analysis
showed a statistically significant, superior effect for combination compared with each
compound alone (PCI2 plus doxorubicin p < 0.001; PCI2 plus cisplatinum, p < 0.05;
Fig. 10). A similar pattern was seen when PCI2 was combined with cisplatinum.
Interestingly, this effect was lost when drugs were administered together for 24 h or
when cells were pretreated with chemotherapy for 24 h prior to PCI2 treatment (data
not shown), suggesting that PCI2 possibly sensitizes STS cells to the effect of
chemotherapy.
Recognizing the anti-STS effects of HDACis as monotherapy and more so in
combination with chemotherapy in vitro we next aimed to assess whether this impact
can also be observed in vivo. Three human xenograft SCID mouse models were
utilized: two local growth models, SKLMS1 growing intramuscular and HT1080
growing subcutaneous, and an experimental lung metastasis model, using HT1080.
Each of these models were used in a four-armed study to evaluate the efficacy of PCI2
alone, doxorubicin or cisplatinum alone, and the combination of PCI2 with either
chemotherapy. Of note, PCI2 was administered first and chemotherapy was
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administered on day 2. For local growth models, the therapy commenced when tumors
were at ~100mm3. Bioluminescence was used to identify the establishment of lung
metastases for the experimental lung metastasis model; once the mice had a
comparable establishment of bioluminescence in the chest cavity, the treatment was
started. The mice were followed for tumor size and body weight and sacrificed when
control group tumors reached 1.5 cm average largest dimension or when
bioluminescence suggested control group had significant pulmonary tumor load.
Effects of tumor growth were statistically assessed using a linear mixed model. To
determine the impact of treatments on tumor weights at termination of study, a linear
regression model was used.
In the first experiment, SKLMS1 xenografts were used and the effects of PCI2,
doxorubicin and their combination were evaluated (Fig. 10A). Treatment with low-dose
doxorubicin alone or PCI2 alone did not significantly affect SKLMS1 xenograft growth
(p = 0.06 and p = 0.015, respectively). Combining PCI2 with low dose doxorubicin
resulted in significant growth inhibition compared to either drug alone (p < 0.0001) (Fig
11A). Tumor volume at study termination was: control 1738mm3 ±334, doxorubicin
1253.1mm3 ±281.5, PCI2 1182mm3 ±329, combination 460.3mm3 ±240. Similarly,
PCI2 and more so PCI2 + doxorubicin resulted in significant reduction in tumor weights
at study termination as compared to control and doxorubicin alone treatment groups (p
= 0.026, < 0.0001, = 0.0023, = 0.047, respectively) (Fig 10B). Average group tumor
weights at study termination were 1.62g ± 0.47 for control, 1.34g ± 0.43 for
doxorubicin, 1.11g ± 0.26 for PCI2, and 0.64g ± 0.24 for combination. H&E staining of
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different treatment arm tumors revealed marked tumor necrosis in PCI2 and
combination treatment groups (Fig 10C); viable tumor sections were
immunohistochemically evaluated for the impact of different therapies on STS cell
proliferation (PCNA) and apoptosis (TUNEL). Average PCNA and TUNEL-positive

Figure 10. Combining PCI2 (50mg/kg/d) with low-dose doxorubicin (1.2mg/kg/biweekly) results
in significant reduction SKLMS1 xenograft growth in SCID mice. A, tumor growth curves
showing a significant synergy between the two drugs (p < 0.0001). B, PCI2 alone effects on
tumor weight were statistically significant (p = 0.026) compared with controls. Most importantly,
the reduction in tumor weight due to combined PCI2/chemotherapy was very statistically
significant compared with the other treatments (p < 0.0001, = 0.0023, and = 0.047 versus
control, doxorubicin, and PCI2 groups, respectively). C, IHC analysis of xenograft specimens
showing enhanced tumor necrosis in PCI2–treated tumors, and most significantly in
combination therapy specimens (H&E), decreased tumor proliferation (PCNA) and increased
apoptosis (TUNEL). No significant differences in CD31 counts were seen; however, a marked
decrease in the number of large, patent blood vessels was discernible in the combination
group. Modified from Figure 3, Lopez et al. Clin Cancer Res 2009;15:3472-3483.
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staining nuclei revealed 88 ± 2 and 20 ± 2.4 for control, 85 ± 1.2 and 16 ± 1.4 for
doxorubicin, 71 ± 2.3 and 19 ± 1.1 for PCI2, and 57 ± 4.6 and 61 ± 18.4 for
combination, respectively. Together these data suggest that combination therapy had
the strongest anti-proliferative and apoptosis-inducing effects (p < 0.05). Sections were
also stained for CD31 to examine therapy effects on tumor-associated vasculature. No
significant differences in CD31 counts were seen; however, markedly decreased
numbers of large, patent blood vessels was discernible in the combination group (Fig
10C).
The second mice experiment evaluated the effects of PCI2, cisplatinum and their
combination on the growth of established HT1080 xenografts (Fig. 11A). Cisplatinum
and PCI2 when administered as single agents had only minimal effects on HT1080
tumor growth. However, significant tumor growth delay was observed with combined
therapy (p < 0.001 versus all other treatment groups; Fig. 11A). This was also
reflected in a significantly reduced tumor volume at study termination for xenografts
treated with therapeutic combination. Tumor volumes were: control 1437.1mm3 ±419,
cisplatinum 1031.5mm3 ±574.8, PCI2 1078.7mm3 ±567.7, combination 254.8mm3
±200 (p < 0.001 for combination compared to all other therapeutic arms). Average
group tumor weights at study termination were 1.23g ± 0.15 for control, 1.01g ± 0.39
for cisplatinum, 1.09g ± 0.54 for PCI2, and 0.36g ± 0.22 for combination (Fig 11B).
Statistical analysis determined that combination therapy significantly reduced tumor
weight as compared to control, cisplatinum, and PCI2 alone (p = 0.0003, = 0.0038,
and = 0.0011, respectively). IHC results were similar to those for the SKLMS1-treated
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tumors described above, showing increased necrosis in PCI2 and combination groups
(Fig. 11C). Decreased proliferation and enhanced apoptosis were most pronounced in
the combination-treated group (average PCNA and TUNEL-positive staining nuclei
were 83 ± 7.1 and 18 ± 0.3 for control, 62 ± 2.8 and 17 ± 2.5 for cisplatinum, 50 ± 2.8

Figure 11. Combining PCI2 (50mg/kg/d) with low-dose cisplatinum (2mg/kg/biweekly) results in
significant reduction of HT1080 xenograft growth in nude mice. A, tumor growth curves showing
a significant synergy between PCI2 and cisplatinum in vivo (p < 0.001). B, a highly statistical
significant tumor weight reduction was observed with combined treatment compared with the
other three groups (p = 0.0003, = 0.0038, and = 0.0011 versus control, cisplatinum, and PCI2
groups, respectively). C, as observed in SKLMS1 xenografts, enhanced tumor necrosis in
PCI2-treated tumors, and most significantly in combination therapy specimens was observed in
HT1080 tumors (H&E). Decreased tumor proliferation (PCNA) and increased apoptosis
(TUNEL) was also seen. No significant differences in CD31 counts were shown; however, a
marked decrease in the number of large, patent blood vessels was discernible in the
combination group. Modified from Figure 4, Lopez et al. Clin Cancer Res 2009;15:3472-3483.
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and 21 ± 5.9 for PCI2, and 38 ± 14.1 and 33 ± 8.6 for combination, respectively; p <
0.05). No significant difference in CD31 positivity was seen among groups, whereas a
reduction in large blood vessels was observed in the combination group.
Together, both these studies suggest that PCI2 alone while highly effective in vitro
does not induce dramatic anti-growth effects in vivo using the dose and regiment
selected. However, combining PCI2 with chemotherapy markedly improves ant-STS
effects in vivo.
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While previous studies focused on the effects of PCI2 ± chemotherapy on local growth
it is even more important to evaluate whether this therapeutic regiment can impact the
growth of STS metastasis which is the cause for STS patient death. A major limitation
to being able to assess the effects of therapy on STS metastatic development and
growth is the current lack of spontaneous STS metastasis models. To that end, for our
studies, we utilized an experimental STS lung metastasis model where HT1080 cells
are injected i.v. into mice tail vein. Lung metastases are commonly visible at ~2 weeks
after injection. To be able to follow-up the development and growth of lung metastases
in these mice, we utilized HT1080 cells stably transduced top express GFP/luciferase
(GL) and metastasis volume was determined using bioluminescence (BLI). Mice were
allocated into six treatment arms after pulmonary metastases were confirmed per BLI
and treatment was initiated (Fig. 12). Drug combination sequencing was done similar
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to the previously mentioned therapeutic
experiments. Experiment was terminated
when BLI readout in control treated mice
suggested an extensive metastatic load (~3
weeks after therapy initiation). At this time
point, as depicted in Fig. 12, readout
demonstrated a markedly reduced

Figure 12. Combining PCI2 (50mg/kg/d)
with low-dose cisplatinum
(2mg/kg/biweekly) or doxorubicin
(1.2mg/kg/biweekly) results in significant
reduction of HT1080 pulmonary metastatic
growth in nude mice. Nude mice injected
with HT1080 cells (1x106/mouse) through
tail vein were followed using
bioluminescence. Treatment (as recorded)
was initiated after bioluminescence
suggested established lung metastases ~3
weeks after cell injections. Sequential
bioluminescence imaging of mice from
each treatment arm show a substantial
increase in luciferase readout in control,
cisplatinum-, doxorubicin-, and PCI2treated groups; decreased readouts were
noted in combination therapy groups. H&E
staining demonstrated only limited lung
metastatic deposits in combination-treated
groups (microscopic metastasis are
marked by arrow heads) as compared to
large metastatic load in other treatment
arms. Modified from Figure 4, Lopez et al.
Clin Cancer Res 2009;15:3472-3483.

pulmonary tumor load in mice treated with
combination therapies as compared to
vehicle, PCI2, or chemotherapy arms alone.
Lung metastases load was also enhanced
on H&E staining of the lungs. Vehicle and
monotherapy-treated lungs demonstrated
massive tumor load replacing almost
entirely the lung parenchyma, whereas
combination treated lungs demonstrated no
or only microscopic results. These
differences were also notable per lung
weights (treated lung metastases weights
were calculated by deducting the estimated
average normal mouse lung weight from

actual lung weight at study termination), where combination therapy-treated lungs
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were significantly smaller in weight compared to vehicle and monotherapy. Average
lung metastases weight per group was 0.55g ± 0.14 for control, 0.62g ± 0.26 for
cisplatinum, 0.48g ± 0.33 for doxorubicin, 0.33g ± 0.20 for PCI2 group, 0.15g ± 0.19 for
PCI2 + cisplatinum, and 0.13g ± 0.14 for PCI2 + doxorubicin. Statistical analysis
revealed a trend toward reduced metastatic load in PCI2 alone treated mice but it did
not reach statistical significance, whereas PCI2 combined with either chemotherapy
resulted in significant lung metastases weight reduction (p < 0.05).
Combined, these data further demonstrates that PCI2/chemotherapy combinations
induce significant effects on the growth of STS lung metastasis and support
consideration of this therapeutic regiment in the clinical setting. Importantly, these data
formed the basis for a currently on-going phase I/II clinical study evaluating “PCI24781 in Combination With Doxorubicin to Treat Sarcoma” (ClinicalTrials.gov
identifier: NCT01027910).
Continuing our pre-clinical studies, as presented next, we sought to identify potential
mechanisms contributing to HDACi sensitivity and especially to the noted
chemosensitivity effects induced in response to HDAC inhibition.
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Studies from our lab have previously demonstrated that Rad51 is commonly
overexpressed in genetically complex STS contributing to the resistance of these
malignancies to conventional chemotherapy; particularly doxorubicin (85). RAD51, a
member of the RecA/Rad51 family of proteins, is a critical regulator of DNA double
strand repair through homologous recombination (86, 87). Hypothesizing that modified
Rad51 expression potentially contributes to the observed chemosensitivity effects of
HDACis in STS, we set to confirm the effects of PCI2 on Rad51 expression. p21
mRNA expression has been shown increase in response to HDAC inhibition with a
variety of HDACi compounds in numerous cell lines of different histologies (50, 88). As
a control, we opted to identify p21 mRNA expression in response to PCI2 in STS.
qRTPCR and RTPCR demonstrated an early (4 h treatment) increase in p21 mRNA
expression in SKLMS1 (p53 mut.) cells when treated with PCI2 (Fig. 13). We then
verified Rad51 expression in response
to PCI2. qRTPCR and RTPCR and WB
analysis validated that PCI2 decreased

RAD51 RNA and protein expression in
STS cell lines, respectively (Fig. 14).

Figure 13. PCI2 induces p21 expression
independent of p53 status in STS cells. qRTPCR and RT-PCR showing a relatively early
(4h treatment) increase in p21 mRNA
expression in SKLMS1 (mutated p53) cells in
response to PCI2. Modified from Figure 5,
Lopez et al. Clin Cancer Res 2009;15:34723483.
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Figure 14. PCI2 induces decreased Rad51 expression in STS cells. A, qRTPCR (upper
panel) and RTPCR (lower panel) showing a PCI2 (0.5μM) time-dependent decrease in
RAD51 mRNA expression. B, PCI2 induced decrease in Rad51 protein expression is shown
in STS cells via Western blotting. Modified from Figure 5, Lopez et al. Clin Cancer Res
2009;15:3472-3483.

Next, we aimed to define the mechanism by which HDACis inhibit RAD51 expression.
First, to identify whether PCI2 affects RAD51 mRNA stability the, transcriptional
inhibitor actinomycin D was used and RAD51 mRNA levels are determined with or
without PCI2 treatment. RAD51 mRNA half-life was found to be comparable between
treated and untreated cells, signifying that PCI2 does not have a direct effect on
RAD51 mRNA degradation (data not shown). To further identify the effect of PCI2 on
RAD51 transcription, we evaluated the recruitment of Poly II (RNA polymerase II) to
the RAD51 gene. The recruitment of Poly II to the p21 gene was used as a control as
we initially showed that PCI2 induced the upregulation of p21 RNA expression (Fig
.13). A chromatin immunoprecipitation (ChIP) assay using an anti-Poly II antibody was
employed showing that PCI2 treatment decreased Poly II recruitment to the RAD51
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gene while it increased the recruitment of Poly II to the p21 gene (Fig. 15). ChIP assay
was also used to determine the association of acetylated histone 3 (ac.H3) and
histone 4 (ac.H4) to the RAD51 and p21
promoters after PCI2 treatment. In PCI2 treated
cells increase of both ac.H3 and ac.H4
recruitment to the promoters of both genes
were identified (Fig. 15). Together, these data

indicate that PCI2 treatment induces the
transcriptional repression of Rad51
accomplished by an increase of acetylated
histone 3 and 4 at the RAD51 promoter.
We next investigated the repressive effect of
PCI2 on RAD51 gene transcription using
RAD51 reporter assays. A luciferase reporter

Figure 15. ChIP showing decreased
Pol II binding to RAD51 gene in
response to PCI2 (0.5μM/24 h); in
contrast increased Pol II binding to
the p21 gene is seen. Binding of
acetylated histones 3 and 4 to the
RAD51 and p21 promoters is
enhanced. No significant nonspecific
IgG binding was observed; input
DNA was used as loading control.
Modified from Figure 6, Lopez et al.
Clin Cancer Res 2009;15:34723483.

construct of the RAD51 promoter region -403 to +63 was transiently transfected into
STS cells tested. Cells treated with PCI2 showed a significant reduction of RAD51
promoter activity. In contrast, a p21 reporter construct demonstrated increased p21
promoter activity after PCI2 treatment (Fig. 16A). To further determine the RAD51
promoter region required for PCI2-induced suppression, we utilized various 5’
truncated promoter regions. All constructs treated with PCI2 significantly showed
reduced luciferase expression (Fig. 16B). Luciferase expression was also significantly
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reduced when the -50Luc region reporter was used, suggesting that the PCI2
response element is at the proximal region of the RAD51 promoter. This promoter
region was initially identified to include an E2F binding site which has been shown to
be important in the transcriptional regulation of RAD51 (89). To determine if PCI2
mediates its anti-Rad51 effects through this cis-regulatory element, the E2F binding
site within the
RAD51 reporter
was mutated.
DMSO treated cells

Figure 16. A, PCI2 (0.5μM/24 h) induces suppression of RAD51
promoter activity while it enhances p21 promoter activation; a −403
bp RAD51 luciferase reporter assay was used. B, PCI2 induced
RAD51 promoter repression is observed even when a reporter
construct consisting of the proximal 50 bp, suggesting that the PCI2
response element is located within this proximal region. Modified from
Figure 6, Lopez et al. Clin Cancer Res 2009;15:3472-3483.

demonstrated a
decrease in
luciferase readout
when the E2F

binding site was mutated, indicating that this site potentially mediates the transcription
of Rad51. Interestingly, PCI2-induced reduction of luciferase expression noted when
using a wild-type reporter construct was eliminated in cells transfected with the
mutated E2F binding site construct (Fig. 17A). This data suggests that PCI2-mediated
transcriptional repression of Rad51 occurs at the proximal region of the E2F binding
site. E2F transcription factors consist of nine family members that can bind to this E2F
site. Previously, E2F1 and E2F4 have been shown to bind the RAD51 promoter (89).
Thus, E2F1 and E2F4 binding to the RAD51 promoter in response to PCI2 treatment
was assessed. Using the ChIP assay, an increase in E2F1 binding was observed in
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cells treated with PCI2, whereas a modest decrease of E2F4 binding was observed
under this condition (Fig. 17B).Together, these data show that HDAC inhibition results
in transcriptional repression of RAD51 mRNA expression. PCI2-induced decrease of
RAD51 RNA represents a possible mechanism for the enhanced chemosensitivity
observed in STS cells in vitro and in vivo.
In summary, studies presented
above demonstrate that human
STS cells are highly sensitive to
the effects of HDACis in vitro,
resulting in cell cycle arrest and
enhanced cell death. Most
importantly, HDAC inhibition
sensitized STS cells to the
effects of chemotherapy; a preclinical observation that is now
being tested in the clinical

Figure 17. A, Mutating the E2F binding site located
within the first 50 bp of the RAD51 promoter construct
resulted in decreased luciferase readout in untreated
cells and most importantly abrogated the PCI2
(0.5μM/24 h) induced RAD51 promoter repression. B,
ChIP analysis showed enhanced E2F1 binding to its
cis element in the proximal RAD51 promoter in
response to PCI2 (0.5μM/24 h); a slight decrease in
E2F4 binding is also observed. Modified from Figure
6, Lopez et al. Clin Cancer Res 2009;15:3472-3483.

setting. Multiple downstream
effectors might contribute to HDACi anti-STS impact; amongst such is Rad51. PCI2induced decrease in Rad51 expression is a potential mechanism underlying HDACi
chemosensitivity effects. While encouraging, it is important to recognize that
genetically complex sarcomas are a heterogeneous malignancy cohort composed of
multiple histologies. Taking this into account upon the completion of the studies above,
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we decided to focus on a single histological subtype, MPNST and determine the
effects of HDACi in this specific malignancy.
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1.3 HDAC down-stream targets potentially contributing to the anti-STS and
chemosensitivity effects of HDACis
HDACs operate by deacetylation of histone and other non-histone proteins resulting in
changes in chromatin condensation. HDAC inhibition thus leads to enhanced protein
acetylation which consequently results in changes in gene expression. In the following
set of studies we sought to identify HDAC inhibition induced genes that their
expression changes might modulate the functional effects observed in STS cells after
HDACi treatment. To that end we conducted gene expression profiling comparing the
expression of genes in STS cells treated with PCI2 (for 4 and 24 h) to those treated
with DMSO (control) only. The custom Codelink oligo microarrays (GE Healthcare)
platform was
utilized including
probes for 2013
genes known to
be highly involved
in tumorigenesis.

A total of 33

Table 5. Codelink oligo microarrays (GE Healthcare) containing a total
of 2013 probes selected for known involvement in cancer to examine
genes (1.6%)
for PCI2-induced gene changes in STS cell lines. Cells were treated
with PCI2 (0.5µM) or DMSO alone for 24 h, and RNA was subjected to
exhibited changed analysis. A total of 33 genes exhibited reproducible change in
expression (20 upregulated and 13 downregulated) in tested cell lines.
expression in
Up-regulated genes are depicted in the upper panel (10 genes with the
highest fold increase are shown), down-regulated genes are in the
response to PCI2
lower panel (10 genes with the highest fold decrease are shown).
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treatment: 20 were found to be overexpressed in 13 to be down-regulated (Table 5).
Amongst the deregulated targets were included genes important for cell cycle
progression: CDKN1A, CHEK1, CDK4; apoptosis: BIRC5, CASP9; transcription
factors: ID2; DNA damage repair: BRCA1, RAD51.
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Figure 18. A, PCI2 induces changes in gene expression in a panel of STS cell lines. B,
PCI2 induces decreased CHK1 and increased CTGF expression in STS cells. RT-PCR
(upper panel) and western blot (lower panel).

Several genes were selected for array confirmation including CDKN1A (p21) and
CTGF (demonstrating 4.6 and 16.2 fold increase, respectively) and CHEK1
(demonstrating 5.3 fold decreased expression) (Table 5). RT-PCR and WB analyses
confirmed the expected changes in the expression of these genes as was found by
gene arrays (Fig. 18). Interestingly, one of the genes identified to be down-regulated in
response to PCI2 treatment was RAD51.
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Section 2: Aim 2: HDACis elicit anti-MPNST effects
2.1 The effects of HDACis on MPNST growth in vitro and in vivo
As described before, after showing the
efficacy of HDAC inhibition in a panel of
complex karyotypic STS subtypes, we
then focused our studies of HDAC
inhibition on a single, aggressive and
dismal genetically complex STS
subtype, MPNST. In this study, we used
primary cultures of human normal
Schwann cells (NSC) as a control, two
sporadic MPNST cell lines (MPNST724
and STS26T), and four NF1-associated
MPNST cell lines (S462, ST88, T265,
and MPNST642). The MPNST642 cell
line was established in our laboratory
(Fig. 19). Prior to initiating our studies
we have first characterized our cell line
panel (Table 6).

Figure 19. A, The cell line termed MPNST642
originated from a recurrent MPNST located in the
forearm of a 21 year old male diagnosed with NF1
at childhood. IHC stains of original tumor are
depicted (X200); H+E demonstrating the
histomorphology of the tumor which stained
positively for vimentin and focally for S100; B,
MPNST642 cells have been growing in culture
continuously for >60 passages (morphology is
depicted, Geimsa staining, upper panel) and they
exhibit anchorage independent growth (lower
panel). DNA fingerprinting confirmed the cell
origin to be from the human tumor and
demonstrated that no cross contamination has
occurred in culture; (continue to next page)
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Figure 19. (Continued from previous page) C, MPNST642 cells (2x106/mouse, s.c. injection)
grow as xenografts in SCID mice: graph demonstrates growth rate (see also table below),
histomorphology is similar to that of original patient tumor although S100 staining is negative
(loss of S100 expression is known to occur with MPNST progression); D, Two additional
MPNST cell lines of those used in our study (STS26T and MPNST724; 1-2x106/mouse)
exhibit s.c. xenograft growth in SCID mice. Growth curves of all 3 available xenografts are
shown together to enable comparison (left upper panel). H+E and IHC staining of xenografts
are depicted (right upper panel) STS26T xenografts are negative for S100 while MPNST724
are focally positive. In addition, tail vein injection of STS26T (1x106/mouse) results in
reproducible lung metastasis – macroscopic and microscopic photographs are shown. The
table summarizes the xenograft growth characteristics of all three human cell lines. STS26T
are commonly used as a cellular model of sporadic MPNST and are widely accepted as a
representative of this disease. MPNST724 have been kindly provided by Dr Jonathan
Fletcher, the original diagnosis was made by a vastly experienced pathology team; S100
positivity in MPNST724 xenografts further supports the MPNST origin of these cells. Modified
from Figure S1, Lopez et al. Cancer Res 2011;71:185-196.

Three pan-HDACis were used for this study: PCI2, SAHA, and MS275 to eliminate the
possibility of compound specific off target effects. All three compounds induced a timeand dose-dependent growth inhibition that was most pronounced in a subset of
MPNST cell lines tested. The graphs depict GI50s at 48 h; 4 MPNST cell lines were
markedly sensitive to PCI2, with GI50s ranging between 0.1 and 0.35µM, whereas the
2 additional cell lines (STS26T and MPNST724) were relatively
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doubling
time (h)

NF1
associated

Ras
active

p53
status

grow
in mice

Lung
metastases

S462

24

negative

Yes

mut.

No

No

ST88

36

negative

Yes

wt

No

No

MPNST642

38

negative

Yes

wt

Yes

No

T265

32

negative

Yes

mut.

No

No

STS26T

19

positive

No

null

Yes

Yes

MPNST724

27

positive

Yes

mut.

Yes

No

Cell lines

Table 6. Human NF1-associated MPNST cell lines: S462, ST88, MPNST642, T265. Human
sporadic MPNST cell lines: STS26T, MPNST724. Doubling time is depicted in hours. All
rNF1-associated cell lines have been confirmed for loss of NF1. Sporadic cell lines retain
NF1. Ras activity was detected in all NF1-associated cell lines and MPNST724; STS26T did
not exhibit Ras activity (Ras activity was detected using a Ras Activity assay Kit, Table 4).
Sequence analysis determined p53 mutation status in all cell lines. Only one NF1-associated
MPNST cell line grows s.c. in SCID mice (MPNST642). Both sporadic cell lines grow s.c. in
SCID mice, but only STS26T develops lung metastases in SCID mice after tail veil injection.

resistant exhibiting GI50s more than the clinically relevant dose (>1µM). NSCs were
resistant to PCI2 growth inhibitory effects. Higher doses of SAHA and MS-275 were
needed to achieve PCI2-equivalent MPNST growth inhibition; however, a similar

Figure 20. Growth-inhibitory effects (48 h) were determined via MTS assays, GI50s are
depicted. One MPNST cell-line subset was highly sensitive to the effects of all 3 drugs
(highest sensitivity to PCI2), whereas a second exhibited relative resistance. No significant
effect on normal human Schwann cells’ (NSC) growth was noted in clinically relevant
therapeutic doses. Modified from Figure 1, Lopez et al. Cancer Res 2011;71:185-196.
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Figure 21. Clonogenic assays showed a similar pattern of response to HDACis The
respective graphs represent the number of colonies counted in experiments; repeated three
times. Modified from Figure 1, Lopez et al. Cancer Res 2011;71:185-196.

response pattern was found for all these drugs, enabling MPNST cell designations to
"sensitive" and "resistant" cohorts (Fig. 20).
This same pattern of sensitivity/resistance to the compounds was observed using
clonogenic assays (Fig. 21). We then determined if this “sensitive” and “resistant”
effect on growth was due to HDACi-induced apoptosis. All three compounds induced
marked apoptosis (Annexin-V/PI staining FACS analysis and western blotting for
cleaved caspase 3) in ”sensitive” cell lines with little or no apoptosis in the ”resistant”
cells (Fig. 22). HDACi-induced acetylation of target proteins was observed in all cells
lines including normal Schwann cells despite variations on the effect on growth (Fig.
23). Previous data have demonstrated that acetylation also occurs in normal cells
(known to be resistant to HDACi effects), suggesting that even though HDACis reach
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and inhibit their targets, additional mechanisms play a role in HDACi-mediated
sensitivity and resistance (81).
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Figure 22. Marked apoptosis was noticed in "sensitive" cell lines but not in "resistant" cell
lines [Annexin V/PI staining FACS analyses (48 h) and cleaved caspase-3 WB]. Modified
from Figure 1, Lopez et al. Cancer Res 2011;71:185-196.

We then tested the in vivo effect of PCI2 (this compound was selected due to its
enhanced effect in vitro) on therapeutic “sensitive” and “resistant” human xenografts.
Similar to the effects observed in vitro, MPNST642 xenografts were highly sensitive to
the inhibitory growth effects of PCI2, while only a minimal effect on tumor growth
occurred in MPNST724 and STS26T xenografts (Fig. 24A). Of note, marked effects
on growth and tumor weight (p = 0.00016 and 0.0004, respectively) were noted in the
MPNST642 experiment even when a relatively low therapeutic dose (25 mg/kg BID)
was used. In contrast, no statistically significant impact (p > 0.05) was found in
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Figure 23. A time- and dose-dependent increase in target protein acetylation was shown
after treatment with either of the compounds in all cell lines (including NSC) independent of
growth inhibitory response (MS-275 is a selective HDAC1/HDAC2 inhibitor and does not
affect tubulin acetylation). Modified from Figure 1, Lopez et al. Cancer Res 2011;71:185-196.

MPNST724 and STS26T experiments even when a high dose of PCI2 (50 mg/kg BID)
was utilized (Fig. 24A). IHC analysis of the tumors from both xenografts reflected this
difference in sensitivity and resistance (Fig. 24B). PCI2-treated MPNST642 xenografts
had a decrease in Ki67 staining (cell proliferation) with an increase in TUNEL positive
cells (p = 0.008 and 0.0008). IHC analysis in the MPNST724 xenografts showed an
opposite effect; no discernible change in Ki67 and TUNEL among vehicle and treated
cohorts. This data further confirms HDACi-induced sensitivity and resistance in NF1associated and sporadic MPNST cells, respectively.
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Figure 24. SCID mice bearing MPNST642 and MPNST724 xenografts were treated with
PCI2 (PCI2; 25 mg/kg/d and 50 mg/kg/d, respectively) or vehicle (10 mice/group). Tumor
growth and weight curves are depicted showing that PCI2 abrogated the growth of
MPNST642 tumors (p = 0.00016 and 0.0004 for tumor size and weight, respectively), but not
of MPNST724 tumors although treated with a higher drug dose; B, H&E showed enhanced
tumor necrosis in MPNST642 PCI2-treated tumors, decreased tumor proliferation (Ki67; p =
0.008), and increased apoptosis (TUNEL; p = 0.0008). No significant differences were found
for MPNST724 xenografts. * statistically significant effects; p < 0.05. A similar experiment
was conducted using STS26T xenografts (data not shown) exhibiting minimal effects of
PCI2; results identical to those observed when treating MPNST724 tumors. Modified from
Figure 2, Lopez et al. Cancer Res 2011;71:185-196.
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2.2 Potential mechanisms of sensitivity
Our results thus far suggest that a subset of MPNST cells are highly sensitive to
HDACi effects. Unraveling the mechanism underlying this sensitivity is highly
interesting from the biological/molecular perspective and can potentially be important
for the appropriate selection of patients to HDACi-based “smart” clinical trials. First, we
asked whether HDACi sensitivity is dependent of all tumor growth rates. Table 7
depicts the average doubling times of our MPNST cell line panel. As can be
ascertained from this data, no direct correlation between HDACi sensitivity and growth
rate could be identified. Next, we sought to determine whether p53 mutational status
possibly correlates with HDACi sensitivity. HDACis are known to induce their effects,
at least in part by p53 activation (90). However, MPNSTs are known to commonly
harbor p53 mutations (91). To that end, we hypothesized that mutated p53 cells might
be more resistant to the effects of HDACis. p53 mutational status of our panel of
MPNST cell lines is depicted in Table 7. No direct correlation between p53 status and
HDACi sensitivity could be identified as the most sensitive cell line (S462) and the
least sensitive cell lines (MPNST724 and STS26T) were found to harbor p53
mutations. Furthermore, to evaluate whether the effects of HDACi in our cells are
exerted at least in part through p53, wild-type p53 ST88 and p53 null STS26T cell
lines were used. Knockdown of p53 combined with PCI2 did not enhance apoptosis
compared to non-target control in ST88 cells, suggesting that the absence of p53 does
not confer resistance to pan-HDACi. Overexpression of p53 combined with PCI2 did
71

not enhance apoptosis compared to control in STS26T cells, suggesting that HDACi
does not enhance sensitivity via p53 (Fig. 25).

Intriguingly, when we evaluated our
results we noticed that all
“sensitive” cell lines are NF1associated while the “resistant” cells
are sporadic MPNSTs (Fig 26A).
While this observation has to be
Figure 25. NF1-associated MPNST cells are highly
sensitive to HDACi; sensitivity is independent of p53
mutational status. p53 siRNA knockdown in cells
harboring the wild type gene (ST88) did not confer
HDACi resistance and transient p53 overexpression in null cells (STS26T) via adeno-p53
transfection did not enhance HDACi sensitivity in
these resistant cells. Modified from Figure S2,
Lopez et al. Cancer Res 2011;71:185-196.

viewed with caution due to the
limited cell line number available,
we thought it is worthy of further
investigation. Of note, this unique
response pattern was not observed
when we tested with doxorubicin or

other molecularly targeted anti-cancer therapies (e.g. the TKR inhibitor, XL184) (data
not shown). Somatic NF1 loss has been suggested in another STS histological
subtype, pleomorphic liposarcoma (PLS) (92); we evaluated our human PLS cell line
cohort, finding that at least one of the three cell lines (Lisa2) exhibited NF1 expression
loss (data not shown). Interestingly, this cell line was also the most sensitive to PCI2.
While not directly related to these MPNST-focused studies, this observation further
suggests a potential role for NF1 loss as an HDACi response biomarker and offers an
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additional cellular model for basic NF1 studies. To determine whether NF1 loss does
contribute to HDACi sensitivity, we knocked down NF1 in MPNST724 and STS26T
cells using specific siRNA constructs (Fig. 26B); Neurofibromin loss resulted in
increased apoptosis in response to HDACi. Together, these data demonstrate a
potential role for NF1 loss in MPNST sensitivity to the pro-apoptosis effects of
HDACis.
Figure 26. A, All HDACi sensitive cells in our
study were found to be NF1 associated (WB
depicting loss of neurofibromin protein
expression) while resistant cells were of
sporadic MPNST origin, expressing NF1. NF1
loss is the hallmark of NF1-associated
MPNST. Several studies have identified
somatic NF1 mutations to occur in a subset of
sporadic MPNSTs, although not uniformly in
all cases (e.g. Bottillo et al. J Path, 2009: 217;
693-710). The exact prevalence and
importance of NF1 loss in sporadic MPNST
tumorigenesis is currently unknown. B, NF1
knockdown in sporadic cell line STS26T
enhanced HDACi-induced pro-apoptotic
effects, further confirming a role of NF1 in
response to the effects of HDAC inhibition.
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Section 3: Aim 2: (Macro)Autophagy as a mechanism of HDACi resistance in MPNST

3.1 HDACis induce autophagosome accumulation in MPNST cells
It is critical to determine the potential mechanisms contributing to the observed
tolerance of some MPNST cells to HDAC inhibitors in order to develop more effective
HDACi-based therapeutic combinations. To evaluate structural changes in “resistant”
cells induced by HDACi, transmission electron microscopy (TEM) was utilized. Many,
autophagosomal structures of various size were observed in PCI2 treated cells, with

Figure 27. TEM images showing ultrastructural changes in MPNST cells in response to PCI
(0.5µM/24 h). A large number of autophagic vesicles were identified (arrows) without
evidence of chromatin condensation, nuclear membranes remained intact further supporting
lack of apoptotic effect. Modified from Figure 3, Lopez et al. Cancer Res 2011;71:185-196.

no morphological features indicative of apoptosis or necrotic cell death (Fig. 27). The
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presence of HDACi-induced autophagosome accumulation was further established
when western blotting for the presence of LC3B conversion and the expression of
LC3B-II. An increased expression of LC3B-II is indicative of an increase in
autophagosome number; all three HDACis enhanced LC3B-II expression (Fig. 28).
STS26T and MPNST724 were stably transduced to express GFP-LC3 and these were
treated with HDACi and monitored via fluorescent microscopy. HDACi treatment
induced an increase in GFP-LC3 puncta, representative of autophagosome
accumulation (Fig. 29). HDACi-induced autophagosomal accumulation was also
observed in vivo.
GFP-LC3 transduced

Figure 28. Increased LC3B-II expression (normalized to actin;
densitometry values are depicted) was noticed after HDACi.
Modified from Figure 3, Lopez et al. Cancer Res 2011;71:185-196.

MPNST cells were
injected s.c. into

SCID mice and when tumors reached 1 cm, mice were treated with PCI2 for 4 days.
On the 5th day a final dose was administered and tumors were collected after 2, 4, and
6 h. Western blot analysis of the tumor samples showed increased LC3B-II conversion
in a time-dependent manner (Fig. 30). Furthermore, TEM identified autophagosome
accumulation in tumor cells in vivo after treatment with PCI2 (Fig. 30).
Interestingly, TEM analyses have demonstrated the potential accumulation of
autophagosomes in NF1-associated, HDACi sensitive, MPNST cells in response to
therapy. However, in contrast to resistant cells, signs of apoptosis were noted in these
cells on TEM (chromatin condensation, membrane blebbing, etc.). Additional assays,
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as per above, confirmed autophagosome accumulation in this MPNST cell line cohort
(Fig. 31, 32).
Together, these experiments demonstrated that HDACi-induced autophagosomal
accumulation occurs in all tested MPNST cell lines. Autophagosome accumulation is
not necessarily a mark of induced autophagy as it can signify either enhanced
autophagic flux or blocked, incomplete autophagy. Multiple additional experiments are
required in order to determine the implications of the above observations.

Figure 29. Cells stably transduced to express GFPLC3 exhibited increased GFP puncta in response to
HDACis. Modified from Figure 3, Lopez et al. Cancer
Res 2011;71:185-196.
Figure 30. WB of STS26T
xenografts’ protein treated with PCI2
(50 mg/kg/d) harvested 2, 4, and 6 h
after final dose showed a timedependent increase in LC3B-II
expression. TEM images showing
autophagosomal structures in
STS26T xenografts. Samples used
for the experiments shown here are
from the same in vivo therapeutic
experiment.
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Figure 31. TEM images showing ultrastructural changes in
NF1-associated MPNST cells in response to PCI2
(0.5μM/24 h). As seen in “resistant” cells (Fig. 28) a large
number of autophagic vesicles can be found after HDACi
treatment. However, prominent features of apoptosis such
as chromatin condensation and loss of nuclear membranes
are also evident. Modified from Figure S3, Lopez et al.
Cancer Res 2011;71:185-196.

Figure 32. Increased LC3B-II
expression was noticed after
treatment of “sensitive cells”
with any of the HDACis. ST88
GFP-LC3 exhibited increased
GFP puncta in response to
HDACi treatment. Modified
from Figure S3, Lopez et al.
Cancer Res 2011;71:185-196.
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3.2 HDACis induce productive autophagy in MPNST cells in vitro and in vivo

Figure 33. AO staining demonstrated increased AVOs in PCI2 treated (0.5uM/24 h) sporadic
and NF1-associated MPNST cells compared to control treated cells, as was further
confirmed via FACS analysis. Modified from Figure 3 and S3, Lopez et al. Cancer Res
2011;71:185-196.

As stated above, additional assays are required to distinguish between enhanced
autophagic flux (productive autophagy) and blocked autophagy. First, staining with the
lysotropic compound acridine orange revealed an increase in acidic vesicular
organelles in PCI2 treated cells compared to control DMSO treated cells; microscopy
and FACS analysis both confirmed this observation (Fig. 33).
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Increased acridine orange staining was seen in both “resistant” and “sensitive” cells
suggesting enhanced productive autophagy in response to treatment. This assay,
however, is not sufficient to conclusively determine productive autophagy and
additional experiments using inhibitors of the final stages of autophagy (Bafilomycin A1
[BFA] and chloroquine [CQ]) are usually needed. Pretreatment (1 h) of MPNST cells
with either lysosome inhibitor followed by PCI2 for 24 h resulted in a higher expression
of LC3B-II compared to control, BFA or CQ alone, and PCI2 alone, providing evidence
for enhanced productive autophagy in response to PCI2 (Fig. 34). Those effects were
noted in both “resistant” (Fig. 34A) and “sensitive” (Fig. 34B) MPNST cell lines.
Similarly, when GFP-LC3 transduced cells were treated with BFA or
CQ, HDACi, and BFA/CQ combined with HDACi, an increase of GFP cleavage from
LC3B was observed in PCI2 treated cells compared to other treatments (Fig. 35A).

Figure 34. Sporadic (panel A) and NF1-associated MPNST cells (panel B) were pretreated (1
h) with low doses of the inhibitors BFA (1 nM) or CQ (1 uM) prior to PCI2 treatment (24 h).
Additional increased LC3B-II expression in response to PCI2 was noticed in the presence of
these inhibitors. Modified from Figure 3 and S3, Lopez et al. Cancer Res 2011;71:185-196.
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Together, these assays support HDACi-induced productive autophagy in MPNST cells
in vitro. GFP-LC3 xenografts were also treated with PCI2, chloroquine, and the
combination (mice were treated with chloroquine 1 day prior to combining with PCI2).
Western blot analysis of the tumor samples showed an increase cleaved GFP in PCI2
treated mice whereas pretreatment with CQ inhibited PCI2-induced GFP cleavage
(Fig. 35B). This data revealed that HDACi-induced autophagy can be recapitulated in
vivo.

Figure 35. A, MPNST724 GFP-LC3 cells (left panel) and ST88 GFP-LC3 (right panel) were
pretreated (1 h) with CQ (1 uM) prior to PCI2 treatment (24 h). GFP cleavage was found in
response to HDACi and was blocked by pretreatment with CQ. Free GFP expression was
found in response to PCI2 treatment. Chloroquine blocked HDACi-induced increases in free
GFP. B, MPNST724 GFP-LC3 xenografts were treated with PCI2, CQ, or their combination.
Free GFP expression was found in response to PCI2 treatment. Chloroquine blocked HDACiinduced increases in free GFP. Modified from Figure 3 and S3, Lopez et al. Cancer Res
2011;71:185-196.
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3.3 Autophagy is a mechanism of therapeutic resistance in MPNST
The role of drug-induced autophagy in cancer remains controversial, whether this
process contributes to cell death or is a mechanism of resistance might be a cellcontext, -compound, -specific consequence (93, 94). To evaluate the role of HDACiinduced autophagy in MPNST we evaluated the impact of autophagy blockade by
genetic (i.e. siRNA) and pharmacological inhibition on the HDACi therapeutic
response. Knockdown of beclin 1, ATG5, and ATG7, genes essential for the induction
of autophagy, was combined with PCI2. Knockdown of these genes, as expected,
inhibited PCI2-induced LC3B conversion (i.e. autophagy) and most importantly
resulted in enhanced apoptosis compared to knockdown or PCI2 treatment alone (Fig.
36-38). Enhanced apoptosis was noted in both “resistant” and “sensitive” MPNST cell
lines; a lower PCI dose was used for the later.

Figure 36. Anti-Beclin siRNA (20 nM pool) knockdown in sporadic (A) and NF1-associated
MPNST cells (B) was confirmed by WB and autophagy blockade was validated using LC3B-II
WB. Enhanced apoptosis in response to PCI2 (sporadic cells 0.5 uM/24 h; NF1-associated
cells (0.1 uM/24 h) was determined by PARP cleavage and Annexin-V/PI FACS analysis.
Modified from Figure 4 and S3, Lopez et al. Cancer Res 2011;71:185-196.
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Figure 37. Anti-ATG5 siRNA (20nM pool) knockdown in sporadic (A) and NF1-associated
MPNST cells (B) was confirmed by RT-PCR and autophagy blockade was validated using
LC3B-II WB. Enhanced apoptosis in response to PCI2 (sporadic cells 0.5uM/24h; NF1associated cells (0.1uM/24 h) was determined by PARP cleavage and Annexin-V/PI FACS
analysis. Modified from Figure 4 and S3, Lopez et al. Cancer Res 2011;71:185-196.

Figure 38. Anti-ATG7 siRNA (20nM
pool) was confirmed by WB and
autophagy blockade was validated
using LC3B-II WB. Enhanced apoptosis
in response to PCI2 (0.5uM/24 h) was
determined by PARP cleavage and
Annexin-V/PI FACS analysis. Modified
from Figure 4, Lopez et al. Cancer Res
2011;71:185-196.
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We next evaluated the effect of pharmacological inhibition of autophagy combined with
HDACi. Again, we used BFA and/or CQ to inhibit lysosomal-mediated degradation of
HDACi-induced autophagosome content. Monotherapy with BFA/CQ and PCI2 had no
effect on the clonogenic potential of MPNST cell lines, but combination of these
compounds resulted in a significant reduction in colony forming capacity (Fig. 39).
Figure 39. Pharmacologic autophagy
inhibition was achieved using BFA
and CQ. None of the compounds
alone significantly affected the
clonogenic capacity of STS26T or
MPNST724; however, significant
effects were noticed after CQ (1uM)
or BFA (1nM) pretreatment of cells
(1 h) followed by PCI2 for 24 h (p <
0.05). Modified from Figure 4, Lopez
et al. Cancer Res 2011;71:185-196.

Combination therapy also resulted in enhanced apoptosis compared to BFA/CQ and
PCI2 alone (Fig. 40). These effects were noted in both “resistant” and “sensitive”
MPNST cell lines; a lower PCI2 dose was utilized for the later. Taken together, our
data strongly demonstrates that autophagy blockade enhances the pro-apoptotic
effects of HDACis in MPNST. This occurs in both cells that are relatively resistant to
HDACi-induced apoptosis as well as cells that are sensitive to these effects. In the
later scenario, combining autophagy blockade with even low doses of HDACis induces
marked cell death.
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Figure 40. Pretreatment with BFA or CQ combined with PCI2 markedly increased apoptosis.
Modified from Figure 4 and S3, Lopez et al. Cancer Res 2011;71:185-196.

While the above results are highly promising, all of these observations were made
using cells growing in culture. At this stage it was thus critical if superior effects of
HDACi/autophagy blockade can be recapitulated in vivo. To that end, mice harboring
STS26T and MPNST724 xenografts were allocated into 4 treatment arms when
tumors reached ~5 mm3: vehicle, CQ, PCI2, CQ combined with PCI2. In the
combination treatment, mice were treated with CQ 24 hr prior to combining with PCI2.
As in previously described experiments (see Fig. 25), the efficacy of PCI2 as
monotherapy was minimal as compared to vehicle control. Similarly, Chloroquine
alone did not significantly impact tumor growth. However, combination therapy
resulted in significant tumor growth inhibition in both xenograft models compared to
vehicle or either compound alone (Fig. 41). MPNST724 xenograft volumes and
weights at study termination were: control 1576.1 mm3 ±573.6 and 1.3 g ±0.2; PCI2
1131.1 mm3 ±257.7 and 1.24 g ±0.1; Chloroquine 925.3 mm3 ±201.8 and 1.1 g ±0.1;
and combination 209.2 mm3 ±44.8 and 0.25 g ±0.1 respectively. STS26T tumor
volumes and weight at study termination were: control 1242.8 mm3 ±120 and 1.4 g
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±0.2; PCI2 985.5 mm3 ±143.8 and 1.1 g ±0.1; Chloroquine 1030.3 mm3 ±144 and 1.2 g
±0.2; and combination 171.7 mm3 ±123 and 0.24 g ±0.1 respectively.

Figure 41. Tumor growth curves/weight bars showing a significant impact of PCI2 + CQ
combination on MPNST724 and STS26T growth (p = 0.04 and p = 0.03, respectively). No
significant effect was noted after either compound alone. *, statistically significant effects; p <
0.05. Modified from Figure 5, Lopez et al. Cancer Res 2011;71:185-196.

Figure 42. TUNEL assay of samples from Fig. 43. Significant increase in apoptosis (TUNEL
staining) was observed in combination-treated xenografts (p < 0.05). *, statistically significant
effects; p < 0.05. Modified from Figure 5, Lopez et al. Cancer Res 2011;71:185-196.
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Immunohistochemical analysis revealed that combination treated tumors had a
significant increase in TUNEL positive cells compared to vehicle or either compound
alone (Fig. 42).
While the above experiment evaluated the effects of treatment on local MPNST
xenograft growth it is critical to assess if this therapeutic regiment affects MPNST lung
metastasis growth. Limited by the lack of spontaneous MPNST lung metastasis mouse
models, we utilized an experimental model where STS26T cells are injected i.v. into
the tail vein. Established lung metastasis develop within 2 weeks after injection, thus
treatment was initiated at that time. Similar to the local growth xenograft models,
combination of CQ with PCI2 significantly inhibited the growth of STS26T lung
metastases compared to either drug alone (Fig. 43). All mice in this therapeutic
experiment had observable macroscopic lung metastases, however, the number of
macroscopic lesions was severely reduced in combination therapy mice compared to
vehicle, PCI2 and Chloroquine alone. The average number of macroscopic lung
metastases were: Vehicle 9.6 ±1.8, PCI2 8.2 ±1.7, Chloroquine 8.5 ±1.7, combination
2.1 ±1.1. This difference between vehicle, PCI2 and Chloroquine alone compared to
combination was highly significant (p >0.001). Average lung weights from each group
also depicted these significant differences: Vehicle 0.6 g ±0.1, PCI2 0.4 g ±0.1,
Chloroquine 0.4 g ±0.1, combination 0.2 g ±0.1. Cumulatively, these data confirm that
autophagy blockade sensitizes MPNST xenografts to the pro-apoptotic effects of
HDACi in vivo.
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Figure 43. STS26T lung metastases bearing mice were treated with PCI2, CQ, or their
combination. A significant decrease in number of visible metastasis (left graph) and average
lung weight (right graph) were found in the combination therapy group (p < 0.05) but not after
treatment with either agent alone. *, statistically significant effects; p < 0.05. Modified from
Figure 5, Lopez et al. Cancer Res 2011;71:185-196.
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Section 4: Aim 2: Molecular mechanisms underlying HDACi induced autophagy in
MPNST
4.1 Autophagy gene array results and confirmation
Unraveling the molecular mechanisms underlying the development of productive
autophagy in response to HDACi are highly important. This information can not only
enhance our current knowledge of the autophagy process but can hopefully result in
the identification of molecules that can be targeted in combination with HDACi to
achieve improved anti-MPNST therapeutic effects. This is especially critical when
realizing that Chloroquine is not exclusively an autophagy inhibitor, having multiple “off
target” effects. To identify potential molecules contributing to HDACi-induced
autophagy, we used a focus PCR-based autophagy array (this platform consists of
primers targeting 84 genes known to play a role in autophagy, 56). RNA was extracted
from MPNST cells treated with PCI2 (0.5uM, 24 h) or with DMSO alone and autophagy
related gene expression changes were determined. Treatment with PCI2 induced the
overexpression of 4 genes and the downregulation of 5 genes in all 4 cell lines tested.
Overexpressed genes CXCR4, TMEM74, and IRGM and downregulated NF-kB were
chosen for array validation. Quantitative RTPCR demonstrated a dose-dependent
increase or decrease in the RNA expression of the selected genes after treatment with
PCI2 (Fig. 44). These PCI2-induced changes in RNA expression also occurred in
samples obtained from in vivo therapeutic experiments (Fig. 45). This data identified a
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variety of HDACi-modified genes potentially important in HDACi-induced autophagy,
warranting additional study.

Figure 44. A focused autophagy PCR array identified several genes to be reproducibly
deregulated in response to PCI2 (0.5uM/24 h). A concordant dose-dependent
increase/decrease in corresponding RNA expression levels was identified (qRTPCR) in both
cell lines after treatment with PCI2 (24 h). Modified from Figure 6, Lopez et al. Cancer Res
2011;71:185-196.

Figure 45. An increase in IRGM, CXCR4, and TMEM74 mRNA and a decrease in NF-kB
mRNA levels were identified by qRTPCR and RTPCR in xenograft tissues retrieved from
experiments described earlier. Modified from Figure 6, Lopez et al. Cancer Res
2011;71:185-196.
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4.2 IRGM as an HDACi target enhancing
Among the genes selected for validation, IRGM exhibited the highest increase in
HDACi-induced RNA expression, and was thus chosen for further evaluation of its
potential role in HDACi-induced autophagy. To determine whether the observed
increase in IRGM is PCI2 specific or is a more general response to HDACi in our cells
we evaluated its expression in response to SAHA and MS-275; both compounds
enhanced the expression of this gene. WB analysis further demonstrated that the
effects on IRGM mRNA were also recapitulated in protein expression levels (Fig. 46).
Figure 46. An increase in IRGM
mRNA was also identified by in
response to SAHA and MS-275
(1uM/24 h). Furthermore, a PCI2induced increase in IRGM protein
was observed. Modified from Figure
6, Lopez et al. Cancer Res
2011;71:185-196.

Next, the impact of IRGM on HDACi-induced autophagy was evaluated. IRGM was
knocked down in MPNST cells using siRNA constructs; KD was confirmed by RTPCR.
These cells as well as cells transfected with non-targeting siRNA constructs (used as
controls) were treated with PCI2. WB analyses confirmed that IRGM KD inhibited LC3
conversion and LC3-II expression in MPNST cells in response to PCI2. Most
importantly, IRGM KD induced apoptosis in MPNST cells in response to HDAC
inhibition (Fig. 47). Together, we found that HDACi-induced expression of IRGM
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enhances productive autophagy and inhibition of this protein enhances the proapoptotic effects of the drug.
Figure 47. IRGM siRNA knockdown
(20nM, pool) resulted in PCI2
(0.5uM/24 h)-induced autophagy
blockade (decreased LC3B-II
expression) and in enhanced PCI2induced apoptosis. Modified from
Figure 6, Lopez et al. Cancer Res
2011;71:185-196.
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Section 5: Aim 3: Effects of HDAC8 inhibition on MPNST
5.1 Effects of HDAC8is on human and murine MPNST cells in vitro
Collectively, we have shown that MPNSTs are highly sensitive to the effects of panHDACi when administered as single agents or in combination with autophagy
inhibitors. However, data stemming from clinical studies suggest that pan-HDACi have
a narrow therapeutic window due to toxicity. Development of HDAC isoform-specific
inhibitors might increase this therapeutic window by eliminating unwarranted side
effects elicited by blocking multiple HDAC enzymes. While no specific inhibitors are
currently available for HDACs 1, 2, or 3, recently, highly selective compounds blocking
the activity of the forth isoform, HDAC8, have been developed. In these final set of
experiments, we sought to evaluate the effects of such inhibitors: PCI-34051 and its
derivative PCI-48012; the later a little less selective but having better PK/PD properties
making it ideal for in vivo studies. For these studies, in addition to testing the effects on
our panel of human MPNST cell lines, we have also utilized several murine MPNST
cell lines derived from tumors spontaneously developed in the MPNST GEM model
(cis NF1-/+/p53-/+). Two such cell lines (MPNST6IEP4 and MPNST6IEP) were provided
by Dr. Luis Parada (UT Southwestern, Dallas, TX) and two additional ones (NF1-TG05 and NF1-TG-09) were developed in our laboratory. HDAC8 inhibition, unlike the
inhibition of other HDACs, was previously demonstrated to not induce the acetylation
of histones and/or tubulin. To confirm that PCI3 and PCI4 do not inhibit other HDACs
we evaluated the expression of acetylated histones and tubulin via WB. As shown in
Fig. 48, induction of histones 3 and 4 and tubulin acetylation was observed in human
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as well as murine MPNST cells after PCI2 treatment but not in response to PCI3 or
PCI4.

Figure 48. Western blot analysis showing HDAC8i (PCI3 and 4, 5uM/24 h) do not induced
increases in histone 3, histone 4, and tubulin acetylation in human (A) and murine-derived
(B) MPNST cells. PCI2 (0.1 – 0.5uM/24h) was used as a positive control for these
experiments.

This data confirms with previously published data demonstrating that histone 3 and 4
and tubulin are not deacetylation targets of HDAC8, at least in certain cellular models
(66, 68). Despite these results, HDAC8 has been shown to deacetylate core histone
proteins (61, 63, 64). KrennHrubec et al. showed that compound 2, a ‘linkerless’
hydroxamate-derived compound with high affinity to HDAC8, when used at high doses
(100uM) induced the expression of acetylated histone 4 and α-tubulin in HeLa and
HEK293 cells. Importantly, compound 2 at 0.8uM was shown to have minimal
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inhibition of HDAC6, a HDAC known to specifically deacetylate tubulin (70). Our data
using PCI3/4 suggests, at least in our MPNST models, that HDAC8 may serve in a
role independent of histone modification. Similar to the work done by Krennhrubec and
colleagues, it will be important to identify if PCI3/4 can induce histone and tubulin
acetylation in our MPNST cells at higher doses than currently used. Of note,
Balasubramanian et al., showed that PCI-34051 (PCI3) did not induce the acetylation
of histones or tubulin in Jurkat cells at doses < 25uM (68). Next, we proceeded to
determine whether HDAC8 inhibitors exhibit any effects on the growth of MPNST cells.
MTS assays (96 h) demonstrated a dose-dependent growth inhibitory effect of PCI3/4
on human and murine-derived MPNST using doses in the micromolar range (Fig 49).

Figure 49. MTS assays demonstrating the effect of HDAC8 inhibition (96 h) on human (A)
and murine-derived (B) MPNST cell growth. Murine-derived MPNST cells exhibited marked
sensitivity to both HDAC8i compared to human MPNST cell lines. Murine MPNST cell
growth was abrogated with lower doses compared to human MPNST cell. Although STS cell
growth inhibition was seen with both agents, a more significant response to PCI2 was
observed in cells tested (as previously demonstrated). Black bars depict PCI3, grey bars
depict PCI4.
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Effective doses of PCI3 were similar to previously reported effective doses in T-cellderived leukemia cell lines (68). Interestingly, PCI3 was not shown to induce
cytotoxicity in solid tumor cell lines of various histology at doses equal or less than
5uM (68). However, Compound 2 was shown to abrogate the growth of neuroblastoma
cell lines (69, 71). Notably, both neuroblastoma and MPNST originate from neural
crest cells. Similarly to the pattern noticed with pan-HDACis, NF1-associated cells, at
least S462, was more sensitive to both HDAC8is compared to sporadic MPNST cell
lines independent of p53 mutational status or growth rate. S462 had a 50% reduction
in cell growth at dose ranges of 1-5uM for both HDAC8i compounds. MPNST642 and
STS26T both had a 50% reduction in cell growth at dose ranges of 5-10uM and 1-5uM
for PCI3 and PCI4, respectively. MPNST724 had a 50% reduction in cell growth at
dose ranges of 5-10uM for both HDAC8i compounds (Fig. 49A). Among human and
murine MPNST, the murine MPNST cells were more sensitive to HDAC8is compared
to human MPNST and required lower doses of both compounds (Fig. 49B). This
pattern seen in human MPNST cells was recapitulated using a clonogenic assay (Fig.
50). The clonogenic capacity of murine-derived MPNST cells was very low where
colonies would not form when 100-500 cells per well (in a 6-well culture plate) were
plated and cultured for >10 days. For human MPNST cells, approximately 100 cells
are all that are required to successfully grow colonies. Due to this unforeseen
characteristic of murine-derived MPNST cells, clonogenic assays were not conducted.
The variation of effect between PCI3 and PCI4 may possibly be due to the nominal
affinity of PCI4 has to HDAC6 compared to PCI3 (data not shown). Overall, these data
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Figure 50. HDAC8i abrogate
human MPNST cell colony
formation capacity. 100 – 200 cells
were initially plated for each cell
line. 24 h after plating, PCI3/4
(5uM) was added to the treatment
wells continuously for 10 – 14
days. Right panel of each cell line,
number of colonies counted in
experiments. Murine-derived
MPNST cells failed to grow
colonies at 100 – 500 cells per
well, therefore the clonogenic
capacity of murine MPNST cells
are yet to be determined.

demonstrate human and murine-derived MPNST growth inhibition in response to the
pharmacological inhibition of HDAC8.
To further investigate the role of HDAC8 inhibition on MPNST growth, we next tested
the effect of both compounds on MPNST cell cycle. To evaluate PCI3/4 effect on cell
cycle without the potential marked increase in sub-G1 fractionation, the MPNST cells
(human and murine) were tested with 5uM of both compounds for 48h. From here on,
these preliminary studies utilized 2 human MPNST cell lines (one NF1-associated and
one sporadic cell line) and 2 murine-derived MPNST cell lines (NF1-TG-09 developed
in our laboratory and MPNST6IEPVI developed by Dr. Luis Parada). PCI2 (used as
control) did not induce an increase in S-phase, but rather a decrease compared to
PCI3/4. PCI2 induced an increase in G1 and G2 in S462 and a marked increase in G2
in STS26T cells. PCI2 induced a modest increase in G1 and G2 in MPNST6IEPVI
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cells. Interestingly, cell cycle analysis revealed a common pattern of HDAC8i-induced
S-phase cell cycle arrest, regardless of p53, NF1 status, and species (Fig. 51).

Figure 51. PI staining/FACS analyses showing the effect of HDACis (PCI2 0.5uM/48 h,
PCI3/4 5uM/48 h) on human and murine-derived MPNST cell cycle progression. PCI2
reduced S-phase with a modest increase in G1 and G2 in S462 cells. STS26T exhibited a
PCI2-induced G2 arrest. The effect of PCI2 on murine-derived MPNST cells was modest. All
3 MPNST cell lines exhibited S-phase arrest when treated with either HDAC8i. Additionally,
an increase in sub G1 population is observed (depicted in the respective histograms),
suggesting cell death.
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STS26T exhibited the greatest increase in PCI3/4-induced S-phase arrest with
reductions in both G1 and G2 fractions. Despite the marked PCI3/4-induced increase
in the S-phase fraction in STS26T, this increase was not statistically significant (p =
0.1 and 0.09 for PCI3 and 4, respectively). In the cell lines tested, PCI4 was shown to
induce a slightly higher increase in the S-phase fraction compared to PCI3. Both
HDAC8is and especially PCI2 induced an increase in the sub-G1 fraction in NF1associated cells with a modest effect in sporadic MPNST cells. Since the sub-G1
fraction potentially indicates apoptosis, we next evaluated the effect of both
compounds on apoptosis. PCI3/4 induced marked apoptosis in human MPNST and
murine-derived MPNST cells (Fig. 52)

Figure 52. HDAC8i (PCI3/4 5uM/96 h) induced human MPNST cell apoptosis (Annexin
V/PI staining FACS analyses). Similar to the “sensitive” and “resistant” pattern observed in
Figure 23, NF1-associated cell line S462 showed marked HDAC8i-induced apoptosis
while these effects were lower in sporadic cell lines. The response of these cell lines to
HDAC8i-induced apoptosis was recapitulated and further confirmed via WB for cleaved
caspase 3 (CC3). Due to the higher sensitivity toward HDAC8i compared to human
MPNST cell lines, murine MPNST cells were treated for 48 h. PCI2 (0.5uM/48 h) and both
HDAC8i (PCI3/4 5uM/48 h) induced marked apoptosis in murine-derived MPNST cells
(Annexin V/PI staining FACS analyses, CC3 WB).
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PCI3 and PCI4 enhanced annexin V positive cells S462, where PCI4 had a
significantly higher effect than PCI3 (p=0.29 and p=0.03 for PCI3 and 4, respectively).
This enhancement of PCI3/4-induced apoptosis was confirmed via an increase in
cleaved caspase 3 (CC3). PCI3 induced an increase in annexin V positive STS26T
cells (p= 0.18) but a significant increase in annexin V positive STS26T cells (p= 0.03)
was observed with PCI4 treatment. PCI3/4-induced apoptosis in STS26T cells was
demonstrated when immunoblotting for cleaved caspase 3 (CC3). Murine-derived
MPNST cells exhibited PCI2-induced as well as PCI3/4-induced apoptosis (48 h). All
three drugs induced significant apoptosis in MPNST6IEP cells as depicted using
Annexin V FACS analysis (PCI2, PCI3, and PCI4, p<0.05) and cleaved caspase 3
(CC3) WB.
These promising in vitro data supports the role of HDAC8 in MPNST warranting further
investigation.

5.2 Effects of PCI4 on the growth of human and murine MPNST in vivo
To investigate the role of HDAC8 inhibition in vivo, we utilized our only human NF1associated MPNST model using MPNST642 cells. This experiment was conducted as
mentioned above (Section 2.1 and ref. 56) while utilizing PCI4 (20 mg/kg BID) instead
of PCI2. During the course of this therapeutic experiment, there was no discernible
xenograft growth variation between the vehicle and PCI4-treated groups as tumors
from both groups grew in parallel (Fig. 53). No noticeable drug-induced toxicities
occurred as the mice remained in relatively good well-being with no weight loss. At
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Figure 53. SCID mice bearing MPNST642 xenografts were treated with PCI4 (PCI4; 20
mg/kg BID) or vehicle (5-6 mice/group). Tumor growth and weight curves are depicted
showing that PCI4 had no effect on the growth of MPNST642 tumors. Tumors were
processed for H&E. Serum and tumors were saved for PD/PK studies to identify drug
concentration circulating in the mice and tumor.

termination of this experiment, tumor volumes and weights were surprisingly
marginally higher in PCI4-treated mice compared to vehicle-treated mice (PCI4-treated
mice average tumor volume and weight: 1906.4 mm3 ±594.8 and 1.96 g ±0.52,
respectively; vehicle-treated mice average tumor volume and weight: 1679.1 mm3
±648.5 and 1.48 g ±0.43, respectively). To test if the lack of effect might be related to
problems with drug accessibility plasma and tissue was collected and saved for future
PK/PD analysis. This therapeutic experiment was repeated using the murine-derived
MPNST6IEPVI cell line. This study was conducted similar to the previous experiment.
Treatment with PCI4 began when palpable tumors reached an average diameter of
~5mm. The growth rate of the MPNST6IEPVI xenografts was fast and thus treatment
occurred for 12 days. Of note, two mice from the vehicle group and one mouse from
the PCI4 treatment began to take on a thin appearance despite the absence of weight
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loss. The abdomen of these thinning mice appeared larger than that of their litter
mates. Aside from these three above-mentioned thin mice, all other mice in both
groups appeared to be in good well-being. During the course and at termination of this
experiment tumors from PCI4 therapy were noticeably small than vehicle-treated
tumors (Fig. 54).

Figure 54. SCID mice bearing MPNST6IEPVI xenografts were treated with PCI4 (20 mg/kg
BID) or vehicle (10 mice/group). Tumor growth and weight curves are depicted showing that
PCI4 abrogated the growth of MPNST6IEPVI tumors (p = 0.001354 and 0.022833 for tumor
size and weight, respectively).
* statistically significant effects; p < 0.05.

PCI4 treatment significantly abrogated tumor volume and weight compared to vehicle
(p= 0.001 and p= 0.02, respectively). At the end of this experiment the average tumor
volume and weight for vehicle-treated mice was 2786.1 mm3 ±396 and 1.96 g ±0.28,
respectively; and average tumor volume and weight for PCI4-treated mice was 1215.1
mm3 ±125 and 1.21 g ±0.11, respectively. When tumors were collected, each mouse
was dissected to evaluate potential spontaneous metastases. The stomach and
intestine of both thin mice from the vehicle group and one thin mouse from the PCI4
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group had numerous metastatic nodules of varying size. The lungs of these mice were
also inspected during the dissection and were suspect of metastasis. Abdominal
tumors and lungs from these mice were processed for H&E slides.
This significant in vivo experiment supports further investigation and the attempt for an
additional in vivo experiment utilizing a human MPNST cell line.

102

Chapter VII: Discussion

These studies revealed important findings with great therapeutic potential. In these
studies we showed the efficacy of pan-HDACi alone and in combination with
conventional chemotherapy in genetically complex STS of various histologies in vitro
and in vivo. Our findings supported the initiation of a clinical trial where PCI-24781 will
be combined with doxorubicin for patients with advanced sarcoma (clinicaltrials.gov).
Our focus then shifted to single histology, MPNST, where we demonstrated panHDACi to have marked anti-MPNST effects in a cohort of NF1-associated MPNST
cells lines in vitro and in vivo. In this study we also identified that our sporadic MPNST
cell lines were relatively “resistant” to the pro-apoptotic effects of HDAC inhibition.
HDACi-induced productive autophagy was identified as a mechanism of resistance in
these cells, and when autophagy blockade was supplemented with HDAC inhibition,
the cells succumbed to HDACi-induced apoptosis in vitro and in vivo. Among the
HDACis currently tested clinically, they inhibit multiple HDAC isoforms, mainly class I
HDACs. Despite their promise, the therapeutic index of these compounds is relatively
low, given their wide spectrum of toxicities (95). By targeting a single, biologically
relevant, HDAC isoform, our expectation was to improve therapeutic efficacy by
reducing the toxicities associated with inhibition of multiple HDAC isoforms. Toward
that end, we used HDAC8-specific inhibitors and tested their potential efficacy on
human and murine-derived MPNST. Our initial data suggests a tumorigenic role
HDAC8 in MPNST. We showed that, similar to T-cell derived leukemia (68) and
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neuroblastoma cells (71), our human and murine-derived MPNST cells were sensitive
to HDAC8 inhibition (doses around 5uM). Both human and murine NF1-associated
MPNST exhibited more sensitivity to HDAC8 inhibition compared to human sporadic
MPNST cells; an observation we previously reported with pan-HDAC inhibitors (56).
Uniquely, all MPNST cell lines tested (both human and murine) exhibited HDAC8iinduced S-phase cell cycle arrest. Most importantly, we demonstrated that HDAC8
inhibition induced significant murine-derived MPNST xenograft growth inhibition in
vivo. As these studies continue to expand, various aspects of these studies harbor
intriguing queries.

Similar to data in our study (50), the synergism among various HDACis combined with
several anti-cancer compounds have been well documented in a variety of
histologically diverse cancers. The synergistic effect usually depends on the
sequencing of the compounds, where pre-treatment with an HDACi sensitizes tumors
cells to the pro-apoptotic effects of chemotherapy. This sequencing enhanced the antiSTS effects of doxorubicin and cisplatinum in both our in vitro and in vivo studies.
Currently, there are more than 100 clinical trials evaluating the effects of HDACis
combined with a variety of chemotherapies (www.clinicaltrials.gov).

The HDACi-induced impairment of the double-strand break repair mechanism
supplemented with DNA damaging compounds has been shown to have a synergistic
role (96, 97). HDACis have been shown to inhibit HR repair, a potential mechanism
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contributing to chemoresistance in some malignancies (96-98). Previously, our lab has
shown the high expression of Rad51 is high in a variety of clinical and cell line STS
subtypes. This overexpression of Rad51, a protein that plays a crucial role in HR, in
STS potentially plays a role in their chemoresistant nature. When we knocked down
(siRNA) Rad51, the STS cells tested succumbed to the pro-apoptotic effects of
doxorubicin (85). Adimoolam and colleagues (98) have previously showed that PCI24781 reduced the expression of Rad51 in a colorectal carcinoma cell line (HCT116).
PCI2-induced down-regulation of Rad51 inhibited HR and radiosensitized these
colorectal carcinoma cells as well as lung carcinoma cell lines (NCI-H460, A549) to
irradiation.
In our study, we showed that PCI2 reduced the mRNA and protein expression of
Rad51 in STS cells of different histology. We showed the PCI2-induced transcriptional
repression of Rad51 to be mediated through increased binding of E2F1 to the Rad51
proximal promoter. E2F1 has been shown to primarily act as a transcriptional activator,
where E2F4 acts as a negative transcriptional regulator. Interestingly, Bindra and
Glazer (99) have shown that during hypoxic conditions, E2F4/p103 complexes binds to
the Rad51 promoter resulting in its downregulation. A negative regulatory role for
E2F1 has also been described in a variety of genes (100-102). Possibly, E2F binding
partners influence the positive or negative role on transcription, where HDACi can
impact the construction of the E2F complexes. HDACis may also induce the
acetylation of E2F proteins, thus enhancing their binding to their respective binding
sites on various promoters (103). Despite these intriguing pre-clinical findings, DNA
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damage repair does not solely depend on Rad51, as this dynamic mechanism utilizes
numerous other molecules.

Other genes (i.e. CHK1, CTGF) identified from our initial gene array may possibly
contribute to the chemoresistant nature of STS. Gene array analysis showed that
CTGF increased by an average of 16-fold and CHK1 decreased by an average of 6fold after PCI2 treatment. The PCI2-induced reduction of RNA and protein were
confirmed for both genes. Lee et al. previously showed that SAHA induced DNA
breaks in both normal as well as transformed cells, where normal cells retained the
ability to repair the HDACi-induced DNA breaks (81). They showed that when CHK1
was inhibited in vitro and in vivo in normal cells, the cells succumbed to the proapoptotic effects of HDACi. The role of CHK1 on chemoresistance has been
supplemented in a variety of studies combining CHK1 inhibition, either by genetic or
chemical inhibition, with a variety of targeted therapies and chemotherapeutic
compounds (104-106). Furthermore, cells with non-functional CHK1 have been shown
to be sensitive to a vast range of DNA damaging compounds or replication inhibitors
(107).
Regarding the role of CTGF, there is evidence that CTGF regulates cancer cell
migration, invasion, angiogenesis, and anoikis. However, CTGF has been associated
with a favorable as well as unfavorable prognosis (108-111). Alterations of CTGF
expression in tumor cells suggests that it may be regulated by epigenetic modifications
of the DNA. Most array data did not suggest CTGF to be regulated by HDACs,
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whereas a variable degree of up-regulation was observed in certain hepatoma cell
lines (112) as well as our STS cell lines. Komorowsky et al. reported upregulation of
CTGF in renal cell carcinoma cell lines and Hep3B cells upon treatment with various
types of HDACis (113). These observations indicate that, in addition to the acetylation
status of the histones, CTGF expression will be determined by cell type-specific
transcription factors, which are direct or indirect targets of HDACs (114).
CTGF has also been shown to serve a tumor suppressor. It can induce apoptosis in
human breast cancer cells (108) and suppress cell proliferation in non–small cell lung
cancer cells (109) and human oral squamous cell carcinoma–derived cells (110).
Furthermore, studies have shown that lower CTGF expression was negatively
associated with survival and mortality in lung adenocarcinoma and colorectal cancer
(115, 111). Again, the biological function of CTGF seems to be cell type specific and it
is probably due to the complex contextual interactions within a specific tumor
environment (114).

The basis for the selective toxicity of cancer cells to HDACis is not known. If aberrant
gene expression were the primary method for HDACi-induced apoptosis, then it would
be expect both normal cells and tumor cells to be equally sensitive to HDACis. As a
matter of fact, providing that the disruption of apoptotic pathways is a critical
occurrence in tumorigenesis, it would be anticipated that normal cells would be much
more sensitive to HDACi-induced cell death than cancer cells. If HDACi-induced cell
death is associated with aberrant mitosis, then the circumstance where cancer cells
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generally lose their cell cycle checkpoints can make these cancer cells more sensitive
to HDAC inhibition (117). The failure to activate two cell-cycle checkpoints that are
present in normal cells is responsible for the tumor-selective action of HDACi (117).
In the context of sensitivity to HDACis, we previously showed that NF1-associated
MPNST are relatively more sensitive to HDACi compared to sporadic MPNST cells. In
the natural history of MPNST, the loss of NF1 is a hallmark of the disease. This RasGAP protein regulates the activity of various Ras isoforms (K-, H-, and N-Ras). The
loss of this gene results in higher Ras activity consequentially promoting tumor survival
and progression. In our study, we showed that NF1-associated MPNST cells were
more sensitive to the pro-apoptotic effects of HDACis compared to sporadic MPNST
cell lines. Sporadic MPNST can manifest in the presence or somatic loss of NF1 (24).
Currently, the precise occurrence and importance of the somatic loss of NF1 in
sporadic MPNST progression is unknown. We showed that both sporadic cells,
STS26T and MPNST724 had NF1. Using a Ras activity assay, STS26T had no Ras
activity, however, despite the presence of NF1, Ras activity was enhanced in
MPNST724. Despite the Ras activity in one sporadic cell lines and not the other,
knockdown of NF1 in both cell lines sensitized the cells to the pro-apoptotic effects of
HDACi. The tumor suppressive role of NF1 is well documented, however, at least in
our study, its loss sensitizes sporadic MPNST cells to HDAC inhibition. Interestingly,
enhanced Ras activity has been shown to sensitize STAT1-deficient cells to panHDACi-induced apoptosis (118).However, regardless of enhanced Ras activity in
MPNST724, the cells succumbed to HDACi-induced apoptosis with NF1 knock down,
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suggesting a potential protective role of NF1 outside of its regulatory role in Ras
activation. In a non-Ras-GAP role, NF1 overexpression has been shown to induce an
increase in the expression levels of the focal adhesion kinase (FAK), and changes in
the activation mitogen-activated protein kinases proteins (MAPKs) (119). This
suggests the presence of a Ras-independent NF1-dependent pathway able to modify
the levels of expression of FAK and the levels of activation of MAPKs. Because FAK
and many proteins recently found to bind NF1 have a role in the cytoskeleton, this
pathway may involve rearrangement of cytoskeletal components that assist in
anchorage independence (120). NF1 knockout has been shown to activate the RhoROCK-LIMK2-cofillin pathway to modify the actin cytoskeleton reorganization and
stimulate cell motility, invasiveness, and cell-cell adhesion, thus leading to the
formation of large cell aggregates. This phenotype is suggestive toward the multiple
neurofibroma formations in NF1 patients (120). From this, it would be interesting to
identify if this pathway is constitutively active in our NF1-associated compared to our
sporadic MPNST cell lines. Activation of this pathway may also explain the presence
of potential spontaneous metastases observed in our MPNST6IEPVI in vivo model.
Identifying the potential activation of this pathway in NF1-associated MPNST and
correlating its activation with metastases may rationalize novel combination
therapeutic strategies for metastatic disease in NF1 patients.
Where a majority of cancer cells tested exhibit sensitivity to pan-HDACis, normal cells
show resistance. As briefly mentioned before, the accumulation of reactive oxygen
species (ROS) is among the many mechanisms of HDACi-induced sensitivity in cancer
109

cells (121-123). Unlike cancer cells, normal cells exhibit a higher expression of
thioredoxin, a natural scavenger of ROS; potentially playing a role in their resistance to
pan-HDACi-induced oxidative stress. This cytoprotective role of thioredoxin to panHDACi was established where knockdown of thioredoxin sensitized normal cells to the
pro-apoptotic effects of pan-HDACi (124). Certain cancer cells overexpress
thioredoxin, potentially giving them a survival advantage toward HDACi-induced
oxidative stress (125, 126). Similar to the effects observed in normal cells, inhibition or
knockdown of this antioxidant in these cancers can enhance the efficacy of panHDACis, potentially making this combination therapy ideal in cancer exhibiting
resistance to HDACis. Pre-clinical screening of tumors with an up-regulation of
thioredoxin would likely denote their probable response to HDACi. As of note,
Subramanian et al., showed that Bax-/- embryonic murine fibroblasts to be resistant to
pan-HDAC inhibition (127).
Other mechanisms of resistance toward HDACis have been documented and
summarized by Fantin and Richon (128). One such mechanism of therapeutic
resistance is therapy-induced autophagy.

In our study, we identified HDACi-induced productive macroautophagy (herein
“autophagy”) as a mode of resistance in MPNST cells in vitro and in vivo.
Autophagy is an intracellular, catabolic process used to degrade and recycle cellular
components via the lysosomal system (129). Autophagy is a dynamic process that
plays an integral role in normal processes maintaining cellular homeostasis. Various
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forms of autophagy have been identified. The bulk, lysosomal-mediated degradation of
long-lived proteins and long-lived/damaged organelles occurs through
macroautophagy. Where macroautophagy is the most studied mechanism, other forms
of autophagy exist: microautophagy is the direct engulfment of cellular constituents by
the lysosome; chaperone-mediated autophagy occurs where only proteins that
possess a certain peptidic consensus sequence are identified by a chaperone complex
and moved to the lysosome. Numerous forms of selective autophagy have also been
identified: pexophagy (selective degradation of peroxisomes), mitophagy (selective
degradation of mitochondria), aggrephagy (selective degradation of proteins
aggregates), xenophagy (selective degradation of foreign bodies; i.e. bacteria, viruses)
are among the various forms of selective autophagy (130).
When studying autophagy, the detection of autophagosome accumulation does not
translate to an increase in autophagic flux. Klionsky et al., have emphasized the utility
of “multiple assays” to properly identify the presence of autophagy as well as the
functionality of this process (79).
Autophagic flux or productive autophagy refers to the complete, unperturbed process
of autophagy beginning with the development of a horseshoe-shaped double
membranous phagophore, which develops around an area of cytoplasmic contents
enclosing the contents in an autophagosome which is then fused with a lysosome at
which the autophagosomal contents are degraded where these degraded components
can be reused by the cell (129). Aside from the homeostatic role of autophagy in
normal cell physiology, autophagic cell death (ACD, type II cell death) was previously
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suggested as a mode of cell death (131, 132). ACD has been suggested as a
misnomer (133) where cell death with autophagy is the likely occurrence
notwithstanding, the archival evidence recently brought forth by Clarke and Puyal that
bone fide autophagic cell death (cell death promoted via autophagy, independent from
apoptosis or necrosis) occurs in some contexts (134). Shao and colleagues showed
that HDAC inhibitors SAHA and butyrate induced cell death that had morphological
features of autophagy, independent of caspase activation in Apaf-1 KO MEF cells,
HeLa cells overexpressing Bcl-XL, and cells treated with caspase inhibitor Z-VADFMK (122). In our studies, we demonstrated that NF1-associated MPNST cells
succumbed to HDACi-induced apoptosis. In the apoptotic bodies of these cells,
numerous autophagosomal structures were identified, suggesting, at least in our
model, that HDAC inhibition induces apoptosis in the presence of autophagy. Although
not yet attempted in our studies, it would be interesting to investigate the outcome of
apoptosis inhibition combined with HDAC inhibition in our MPNST models (e.g.
caspase inhibitor Z-VAD-FMK combined with HDACi). The cross-talk among the
autophagic and cell death pathways is well established (135). For instance, Pyo and
colleagues showed that ATG5, a protein important during formation of the extending
autophagosomal membrane, interacts with Fas-Associated protein with Death Domain
(FADD) to induce interferon-γ-mediated cell death in HeLa cells (136). Furthermore,
Yousefi et al. demonstrated that ATG5 can be cleaved in a calpain-dependent manner,
resulting in a “switch” from autophagy to apoptosis (137). Although not yet studied in
our NF1-associated MPNST model, the presence of numerous autophagosomal
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structures in HDACi-induced apoptotic bodies (Fig. 32) suggests the aforementioned
cross-talk among these dynamic processes; NF1-associated cells were succumbing to
HDACi-induced apoptosis in the presence of autophagy, rather than dying of
autophagic cell death.
While the controversy between ACD and the therapy-induced protective role remains,
a majority of studies have pointed out that anti-cancer therapy-induced autophagy
serves in the survival of cancer cells (138-140).
The deregulation of autophagy-related genes has been shown to augment
tumorigenesis in some malignancies (141). In the case of many breast-related
malignancies, BECN1 is monoallelically deleted resulting in deregulated autophagy
(142, 143), indicating the tumor suppressive role of autophagy. Tumor cells with
functional autophagic machinery can circumvent cell death potentially manifested in
the form of anti-cancer therapy or bio-energetic stress (144).

As in the case with our work in MPNST, a wide variety of studies have shown tumor
growth inhibition and the augmentation of cell death when therapies that induce
autophagy are initially supplemented with the inhibition of autophagy (145-147).
A variety of methods, either being genetic or pharmacological inhibition are used to
study the effects of autophagy inhibition. With current methods, autophagy can be
inhibited at induction or the early steps of the formation of the autophagosome and at
the stage of lysosomal-mediated degradation. Tumors cells that use therapy-induced
autophagy as a mode of resistance; inhibition at either of the abovementioned stages
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of autophagy enhances tumor cell growth inhibition and cell death. We showed that
regardless of autophagic stage inhibition, either by inhibiting induction with Beclin1 or
ATG5/7 siRNA or by inhibiting lysosomal-mediated degradation with chloroquine or
BFA, the pro-apoptotic effects of HDACi in MPNST were enhanced in vitro and in vivo.
Our data enhanced the current knowledge and importance of therapy resistance
mediated through therapy-induced autophagy, and further complements the impetus
toward the inhibition of autophagy in the clinical setting. Among the compounds used
to inhibit autophagy, chloroquine and its derivatives are currently the only autophagy
inhibitors used in the clinic. While chloroquine has been used for the treatment of
malaria and is currently being used in clinical trials as an autophagy inhibitor, this
compound has some off- target effects outside of autophagy (147). The lack of
autophagy-specific inhibitors for clinical use warrants the development and/or
identification of novel inhibitors which may support the role of autophagy in the context
of cancer therapy. The identification/development of novel autophagy inhibitors can
potentially lead to the clinically relevant development of novel combination therapies
beyond the current, sole use of chloroquine. It is important to form an understanding
regarding the selective manipulation of autophagy in therapeutically specific
circumstances. In our studies we showed that HDACi induces the expression of IRGM,
TMEM74, and CXCR4 potentially contributing the HDACi-induced autophagy observed
in our MPNST cells. While the role of autophagy in these proteins has been identified
(148-150), their individual role in the autophagic machinery and contribution toward
HDACi-induced autophagy and chemoresistance remains to be discovered. As a proof
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of concept, we showed that when IRGM was genetically inhibited by siRNA, HDACiinduced autophagy was blocked leading to the increase of HDACi-induced apoptosis.
As this initial pre-clinical data is forthcoming, it will be important to expand these
studies further with the hopes of potentially identifying “druggable” targets in a novel
manner to inhibit autophagy.

It will also be important to identify the role of HDAC inhibition on these inducible
targets; which individual HDAC or combination of HDAC isoforms induces autophagy,
and which of these scenarios induce the expression of certain genes (i.e. IRGM,
TMEM74, CXCR4) that induce autophagy? Identifying these specificities will broaden
the current, yet limited knowledge on the aforementioned subject with efforts geared
toward clinical practicality.

Where we showed the significant anti-STS and anti-MPNST effects exerted by panHDACis, we also began initial studies observing the effects by inhibiting individual
HDAC isoforms, namely HDAC8. In the milieu of normal human tissues, HDAC8 has
been shown to be exclusively expressed by cells showing smooth muscle
differentiation, including visceral and vascular smooth muscle cells, myoepithelial cells,
and myofibroblasts, and is mainly detected in the cytosol (66). Waltregny et al. showed
that HDAC8 overexpression in murine fibroblasts formed cytoplasmic stress fiber-like
structures that co-localized with the smooth muscle cytoskeleton protein smooth
muscle α-actin.
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HDAC8 has also been shown to potentially be a more sensitive marker than desmin
and h-caldesmon in epithelioid smooth muscle tumors, where HDAC8 detection may
be useful in serving in the differential diagnosis of uterine-derived mesenchymal
tumors (67). As these studies have identified the practical use of HDAC8 clinically, little
is known about molecular contributions in normal and cancer cells. The identification of
acetylated targets of HDAC8 has been very minimal. Recently, Karolczak-Bayatti and
colleagues showed HDAC8 can interact with Hsp20 to affect its acetylation (151). In
their study they used a HDAC8 inhibitor that augmented Hsp20 acetylation with no
increase of histone acetylation or discernible global gene expression changes. The
effects they observed were associated with significant inhibition of spontaneous and
oxytocin-augmented contractions of ex vivo human myometrial tissue strips. A
possible mechanism by which Hsp20 acetylation can affect myometrial activity is by
the liberation of cofilin, which will regulate contraction in smooth muscle cells (151).
A notable observation in our study was HDAC8i-induced increase in the S-phase in
human and murine-derived MPNST cells regardless of their NF1 and p53 status. This
unique cell cycle arrest occurred with both HDAC8 inhibitors (PCI3 and PCI4) whereas
pan-HDACi induced either G1- or G2-cell cycle arrest in sporadic and human and
murine-derived NF1-associated MPNST cells.

S-phase checkpoint has been shown to be mediated by ATR and Chk2 in human cells
in response to DNA damage and replication-stress conditions (152). The S-phase
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checkpoint can be categorized into three checkpoints: replication, S-M, and intra-Sphase checkpoint. The replication checkpoint initiates when the replication forks get
stalled due to a stress (i.e. depletion of dNTP pools, inhibition of DNA polymerases,
DNA damage). S-M checkpoint certifies that cells wont attempt to divide before the
whole genome becomes duplicated. DNA double-strand breaks which are created just
outside the active replicon activates the the intra-S-phase checkpoint. Unlike the other
two S-phase checkpoints, this checkpoint does not get activated in response to
disruption at the replication fork.

Notably, none of the S-phase checkpoints require p53 (153, 154) for their activation.
As we have yet identified a role for HDAC8 during S-phase of the cell cycle, Deardorff
and colleagues recently reported that structural maintenance of chromosomes 3
(SMC3) is a deacetylation target of HDAC8 in HeLa cells (155). SMC3 is a member of
the SMC family of proteins (156, 158). This protein is a vital component of a multiprotein cohesin complex that holds sister chromatids together during mitosis,
facilitating proper segregation of the chromosome (156). Acetylation of SMC3 has
been shown to occur and play an essential role during S-phase in both yeast and
human systems (158). Where we have shown possible S-phase arrest after treatment
with PCI3/4, Deardorff et al., showed unaltered cell cycle progression in HeLa cells in
the presence of HDAC8 inhibition (i.e. inhibition of HDAC8 was performed using
siRNA and/or 25uM, PCI-34051). Identification of this HDAC8-SMC3 interaction
among other potential HDAC8 regulated S-phase proteins will enhance current
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knowledge on the role of HDAC8 in cell cycle progression. It will also be essential to
determine the effect of HDAC8 inhibition on the cell cycle progression of normal cells.
If HDAC8 inhibition induces bona fide S-phase arrest in MPNST cells, it may be ideal
to combine HDAC8 inhibition with antimetabolitic compounds (e.g. 5-fluorouracil,
cytarabine, gemcitabine, etc.), which exert their cytotoxic effects during S-phase.

This is but one aspect on the role of HDAC8 in genetically complex STS as we plan to
continue to develop our basic knowledge on this subject. This study has led to
invaluable information that not only enhances current knowledge on the biology of
genetically complex STS, namely MPNST, but also the impetus for novel therapies for
patients with these malignancies.
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Chapter VIII: Conclusions and future directions

In this work we have shown the therapeutic efficacy of pan-HDACis in combination
with chemotherapy for the treatment of complex karyotypic STS. Our initial study
(Lopez et al. 2009) helped support the rational that lead to a clinical trial combining
PCI2 with conventional chemotherapy for patients with high grade STS.
Similar to the anti-STS effect of pan-HDACis in STS cells of various histology, panHDACis were shown to have a significant anti-MPNST effect in NF1-associated, but
not in sporadic MPNST. This dichotomy among the NF1-associated and sporadic
MPNST cohorts lead us to the identification of HDACi-induced productive autophagy;
an implied mechanism of therapeutic resistance observed in a variety of pre-clinical
and clinical settings. Inhibition of HDACi-induced productive autophagy enhanced the
pro-apoptotic effects of HDACi in vitro and in vivo. These data opened a variety of
current and future avenues exploring the vast role HDAC inhibition and the
contribution toward anti-STS effects. One such avenue was to identify the role of
individual HDAC isoforms in STS. The unique pattern of “sensitivity” and “resistance”
to pan-HDACi in our MPNST model lead us to further dissect this distinction based on
the contribution of class I HDAC isoforms. Of the class I HDAC isoforms, due to its
unique catalytic structure compared to other HDACs of this class (i.e. HDAC1, 2, 3),
HDAC8-specific inhibitors have been developed. To elucidate the contribution of
individual HDACs in MPNST we utilized HDAC8-specific inhibitors in vitro and in vivo.
Initial data demonstrated that both HDAC8 inhibitors abrogated human and murinederived MPNST cell growth by uniquely inducing S-phase arrest and inducing cell
119

death in vitro. Most importantly, HDAC8 inhibition significantly abrogated murinederived MPNST xenograft growth in vivo.

Future studies will be to identify the expression of HDAC8 in normal nerve,
neurofibroma, and MPNST clinical samples (TMA) to distinguish a possible correlation
with the progression of the disease. HDAC8 has been reported to be a nuclear as well
as cytoplasmic protein. As briefly mentioned above, knowledge of its role in either
cellular compartment is limited and is cell context specific. Determining the sub-cellular
localization of HDAC8 in clinical samples as well as tumor cells lines will be
translationally pertinent. Preliminary effects reported in this study using the HDAC8
inhibitors will be supplemented with the utility of siRNA, specific for HDAC8. Taking
into consideration of future studies, inhibiting HDAC8 with either siRNA or compound
may yield variations in biological outcome. Pharmacological inhibition of HDAC8 will
inhibit the enzymes ability to deacetylate its targets, however, this inhibitory method
may not disrupt functional multi-protein complex potentially containing HDAC8. siRNA
targeting HDAC8 would not only inhibit deacetylation of its targets, but it would also
disrupt multi-protein complexes where HDAC8 plays a role. With the aforementioned
scenario in mind, the potential identification of binding partners and acetylation targets
of HDAC8 will also be explored using both siRNA and PCI3/4 in high throughput
experiments. This method will be carried out by isolating acetylated proteins after
HDAC8 inhibition followed by mass spectrometry analysis. Furthermore, gene
expression patterns correlating with therapeutic response will be established. To
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further complement the experiments proposed above and identify potential gene
expression signatures predictive of HDAC8 inhibition response as well as HDAC8
inhibition-induced gene expression changes that might correlate with enhanced
therapeutic response gene array analysis on control and HDAC8-inhibition-treated
cells (siRNA and PCI3/4) will be performed.
Potential studies mentioned above will hopefully demonstrate significant efficacy of
HDAC8 inhibitors in MPNST preclinical models, thus forming a basis for design of
‘smart’ personalized, and future STS clinical trials. HDAC8 is an understudied HDAC
isoform; comprehensive investigation to determine HDAC8 expression, localization,
function and molecular driven mechanisms is unequivocally warranted.
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